enVVeno Medical (NVNO) 10-K 14 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 13, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Hancock Jaffe Laboratories, Inc.
Entity Central Index Key	0001661053
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Public Float			$ 25,516,058
Entity Common Stock, Shares Outstanding		14,167,698
Trading Symbol	HJLI
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 2,740,645	$ 77,688
Accounts receivable, net	32,022	35,181
Prepaid expenses and other current assets	64,306	57,544
Total Current Assets	2,836,973	170,413
Property and equipment, net	26,153	23,843
Intangible assets, net	666,467	1,109,410
Deferred offering costs		880,679
Security deposits and other assets	29,843	30,543
Total Assets	3,559,436	2,214,888
Current Liabilities:
Accounts payable	1,077,122	1,451,244
Accrued expenses and other current liabilities	412,871	903,594
Accrued interest - related parties		20,558
Convertible notes payable, net of debt discount		1,574,832
Convertible note payable - related party		499,000
Notes payable		275,000
Notes payable - related party		270,038
Deferred revenue - related party	33,000	103,400
Derivative liabilities		3,076,918
Total Liabilities	1,522,993	8,174,584
Commitments and Contingencies
Stockholders' Equity (Deficiency):
Preferred stock, par value $0.00001, 10,000,000 shares authorized: no shares issued or outstanding
Common stock, par value $0.00001, 50,000,000 shares authorized, 11,722,647 and 6,133,678 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively	117	61
Additional paid-in capital	50,598,854	24,389,307
Accumulated deficit	(48,562,528)	(35,519,819)
Total Stockholders' Equity (Deficiency)	2,036,443	(11,130,451)
Total Liabilities, Temporary Equity and Stockholders' Equity (Deficiency)	3,559,436	2,214,888
Redeemable Convertible Series A Preferred Stock [Member]
Current Liabilities:
Redeemable Convertible Preferred Stock		3,935,638
Redeemable Convertible Series B Preferred Stock [Member]
Current Liabilities:
Redeemable Convertible Preferred Stock		$ 1,235,117

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	11,722,647	6,133,678
Common stock, shares outstanding	11,722,647	6,133,678
Redeemable Convertible Series A Preferred Stock [Member]
Redeemable preferred stock, par value	$ 0.00001	$ 0.00001
Redeemable preferred stock, shares issued	0	1,005,700
Redeemable preferred stock, shares outstanding	0	1,005,700
Redeemable preferred stock, liquidation preference	$ 0	$ 10,801,863
Redeemable Convertible Series B Preferred Stock [Member]
Redeemable preferred stock, par value	$ 0.00001	$ 0.00001
Redeemable preferred stock, shares issued	0	253,792
Redeemable preferred stock, shares outstanding	0	253,792
Redeemable preferred stock, liquidation preference	$ 0	$ 3,103,416

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Total Revenues	$ 186,552	$ 422,111
Cost of revenues		419,659
Gross Profit	186,552	2,452
Selling, general and administrative expenses	6,482,953	5,455,963
Research and development expenses	1,238,749	649,736
Loss on Impairment of intangible asset	319,635
Loss from Operations	(7,854,785)	(6,103,247)
Other Expense (Income):
Amortization of debt discount	6,562,736	1,710,130
(Gain) on extinguishment of convertible notes payable	(1,481,317)	(257,629)
Interest expense, net	298,161	209,506
Change in fair value of derivative liabilities	(191,656)	26,215
Total Other Expense (Income)	5,187,924	1,688,222
Net Loss	(13,042,709)	(7,791,469)
Deemed dividend to preferred stockholders	(3,310,001)	(459,917)
Net Loss Attributable to Common Stockholders	$ (16,352,710)	$ (8,251,386)
Net Loss Per Basic and Diluted Common Share:	$ (1.75)	$ (1.35)
Weighted Average Number of Common Shares Outstanding: Basic and Diluted	9,362,474	6,126,824
Product Sales [Member]
Revenues:
Total Revenues		$ 184,800
Royalty Income [Member]
Revenues:
Total Revenues	116,152	137,711
Contract Research - Related Party [Member]
Revenues:
Total Revenues	$ 70,400	$ 99,600

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)		Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016		$ 61	$ 23,508,930	$ (27,728,350)	$ (4,219,359)
Balance, shares at Dec. 31, 2016		6,123,481
Exchange of accrued interest for common stock			1,973		1,973
Exchange of accrued interest for common stock, shares		197
Stock-based compensation: Amortization of stock options			801,624		801,624
Stock-based compensation: Common stock issued to consultants			76,780		76,780
Stock-based compensation: Common stock issued to consultants, shares		10,000
Net loss				(7,791,469)	(7,791,469)
Balance at Dec. 31, 2017		$ 61	24,389,307	(35,519,819)	(11,130,451)
Balance, shares at Dec. 31, 2017		6,133,678
Common stock issued in initial public offering	[1]	$ 17	6,082,427		6,082,444
Common stock issued in initial public offering, shares	[1]	1,725,000
Derivative liabilities reclassified to equity			3,594,002		3,594,002
Redeemable convertible preferred stock converted to common stock		$ 18	5,170,737		5,170,755
Redeemable convertible preferred stock converted to common stock, shares		1,743,231
Common stock issued in connection with May Bridge Notes		$ 1	228,965		228,966
Common stock issued in connection with May Bridge Notes, shares		55,000
Common stock issued in satisfaction of Advisory Board fees payable			90,000		90,000
Common stock issued in satisfaction of Advisory Board fees payable, shares		30,000
Common stock issued upon conversion of convertible debt and interest		$ 17	8,252,669		8,252,686
Common stock issued upon conversion of convertible debt and interest, shares		1,650,537
Common stock issued upon conversion of related party convertible debt and interest		$ 1	517,741		517,742
Common stock issued upon conversion of related party convertible debt and interest, shares		120,405
Common stock issued upon exchange of related party notes payable and interest			150,553		150,553
Common stock issued upon exchange of related party notes payable and interest, shares		35,012
Common stock issued in satisfaction of deferred salary			200,000		200,000
Common stock issued in satisfaction of deferred salary, shares		44,444
Stock-based compensation: Amortization of stock options			864,625		864,625
Stock-based compensation: Common stock issued to consultants		$ 2	878,828		878,830
Stock-based compensation: Common stock issued to consultants, shares		185,340
Stock-based compensation: Warrants granted to consultants			179,000		179,000
Net loss				(13,042,709)	(13,042,709)
Balance at Dec. 31, 2018		$ 117	$ 50,598,854	$ (48,562,528)	$ 2,036,443
Balance, shares at Dec. 31, 2018		11,722,647
[1]	net of offering costs of $2,542,555

Statements of Changes in Stoc_2

Statements of Changes in Stockholders' Equity (Deficiency) (Parenthetical) - USD ($)	Dec. 31, 2018	Jun. 04, 2018	Dec. 31, 2017
Net offering cost			$ 880,679
Initial Public Offering [Member]
Net offering cost	$ 2,542,555	$ 2,542,555

Statements of Cash Flows

Statements of Cash Flows - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Cash Flows from Operating Activities
Net loss		$ (13,042,709)	$ (7,791,469)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount		6,562,736	1,710,130
Gain on extinguishment of convertible notes payable		(1,481,317)	(257,629)
Stock-based compensation		1,922,455	878,404
Depreciation and amortization		133,419	139,213
Change in fair value of derivatives		(191,656)	26,215
Loss on Impairment		319,635
Changes in operating assets and liabilities:
Accounts receivable, net		3,159	(11,681)
Inventory			90,908
Prepaid expenses and other current assets		(6,762)	(11,495)
Security deposit and other assets		700	(700)
Accounts payable		(294,122)	545,385
Accrued expenses		(210,976)	377,079
Deferred revenue - related party		(70,400)	103,400
Total adjustments		6,686,871	3,589,229
Net Cash Used in Operating Activities		(6,355,838)	(4,202,240)
Cash Flows from Investing Activities
Collection of receivable for sale of assets			166,250
Issuance of note receivable to related party			(160,000)
Receipts from collections of note receivable to related party			160,000
Advances to related party			(206,000)
Receipts from repayment of related party advances			216,000
Purchase of property and equipment		(12,422)	(10,938)
Net Cash (Used in) Provided by Investing Activities		(12,422)	165,312
Cash Flows from Financing Activities
Proceeds from initial public offering, net	[1]	7,657,427
Initial public offering costs paid in cash		(706,596)	(209,964)
Proceeds from issuance of notes payable			275,000
Repayments of notes payable		(1,125,000)
Proceeds from issuance of note payable to related party			311,000
Repayments of notes payable - related party		(120,864)	(174,734)
Proceeds from issuance of notes payable, net of commission		722,500
Proceeds from issuance of convertible notes, net	[2]	2,603,750	2,564,400
Proceeds from issuance of redeemable Series B preferred stock and warrant, net	[3]		1,292,400
Net Cash Provided by Financing Activities		9,031,217	4,058,102
Net Increase in Cash and Cash Equivalents		2,662,957	21,174
Cash and cash equivalents - Beginning of year		77,688	56,514
Cash and cash equivalents - End of year		2,740,645	77,688
Supplemental Disclosures of Cash Flow Information:
Cash Paid During the Period For: Interest, net		286,551	105,938
Non-Cash Investing and Financing Activities
Conversion of convertible note payable - related party and accrued interest into common stock		517,742
Exchange of note payable - related party and accrued interest into common stock		150,553	1,973
Fair value of placement agent warrants issued in connection with preferred stock offering included in derivative liabilities			57,283
Fair value of warrants issued in connection with convertible debt included in derivative liabilities		1,046,763	870,966
Embedded conversion option in convertible debt included in derivative liabilities		1,239,510	2,349,560
Derivative liabilities reclassified to equity		6,059,823
Conversion of convertible notes payable and accrued interest into common stock		5,743,391
Conversion of preferred stock into common stock		$ 5,170,755
[1]	Net of offering costs paid from escrow of $967,573
[2]	Net of cash offering costs of $186,100
[3]	Net of cash offering costs of $175,196

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical) - Initial Public Offering [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net of offering costs paid from escrow	$ 967,573
Net of cash offering costs	$ 186,100	$ 175,196

Business Organization and Natur

Business Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	Note 1 – Business Organization and Nature of Operations Hancock Jaffe Laboratories, Inc. (“Hancock Jaffe” or the “Company”) is a development stage company developing biologic-based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. HJLI’s products are being developed to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the type of treatment. Our two lead products which we are developing are the VenoValve®, a porcine based device to be surgically implanted in the deep venous system of the leg to treat a debilitating condition called chronic venous insufficiency (“CVI”), and the CoreoGraft®, a bovine based conduit to be used to revascularize the heart during coronary artery bypass graft (“CABG”) surgeries. Our third product is a Bioprosthetic Heart Valve (“BHV”) which has the potential to be used for pediatric heart valve recipients. All of our current products are being developed for approval by the U.S. Food and Drug Administration (“FDA”). Our current business model is to license, sell, or enter into strategic alliances with large medical device companies with respect to our products, either prior to or after FDA approval. The Company also realizes sub-contract manufacturing and royalty revenue from sales of the ProCol® Vascular Bioprosthesis for hemodialysis patients with end stage renal disease, which has been approved by the FDA, as well as revenue from research and development services performed on behalf of Hancock Jaffe Laboratory Aesthetics, Inc. (“HJLA”), (in which the Company owns a minority interest as described in Note 4 to the Financial Statements – Significant Accounting Policies - Investments

Initial Public Offering

Initial Public Offering	12 Months Ended
	Dec. 31, 2018
Initial Public Offering
Initial Public Offering	Note 2 - Initial Public Offering On May 30, 2018, the Company’s registration statement on Form S-1 relating to its initial public offering of its common stock (the “IPO”) was declared effective by the Securities and Exchange Commission (“SEC”). The Company completed the IPO with an offering of 1,500,000 units (the “Units”) at $5.00 per unit on June 4, 2018, each consisting of one share of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), and a warrant to purchase one share of common stock with an exercise price of $6.00 per share. Aggregate gross proceeds from the IPO were $7,500,000, before underwriting discounts and commissions. On June 8, 2018, the underwriters notified the Company of their exercise in full of their option to purchase an additional 225,000 Units (the “Additional Units”) to cover over-allotments. On June 12, 2018, the underwriters purchased the Additional Units at the IPO price of $5.00 per Unit, generating $1,125,000 in gross proceeds before underwriting discounts and commissions.

Going Concern and Management's

Going Concern and Management's Liquidity Plan	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management' s Liquidity Plan	Note 3 – Going Concern and Management’s Liquidity Plan The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern for the next twelve months from the filing of this Form 10-K. The Company incurred a net loss of $13,042,709 during the year ended December 31, 2018 and had an accumulated deficit of $48,562,528 at December 31, 2018. Cash used in operating activities was $6,355,838 for the year ended December 31, 2018. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the issuance date of the financial statements. As of December 31, 2018, the Company had a cash balance of $2,740,645 and working capital of $1,313,980. The Company expects to continue incurring losses for the foreseeable future and will need to raise additional capital to sustain its operations, pursue its product development initiatives and penetrate markets for the sale of its products. Management believes that the Company could have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means. However, there is a material risk that the Company will be unable to raise additional capital or obtain new financing when needed on commercially acceptable terms, if at all. The inability of the Company to raise needed capital would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to curtail or discontinue its operations, liquidate and/or seek reorganization in bankruptcy. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	Note 4 – Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance related to the Company’s deferred tax assets, and the valuation of warrants and derivative liabilities. Deferred Offering Costs Deferred offering costs, which primarily consist of direct, incremental professional fees relating to the IPO, have been capitalized within non-current assets and were offset against the IPO proceeds upon the consummation of the IPO. Deferred offering costs of $2,542,555, consisting primarily of legal, accounting and underwriting fees of which $880,679 of the deferred offering costs were incurred in 2017, and the full amount was charged to additional paid in capital upon the consummation of the IPO on June 4, 2018. Investments Equity investments over which the Company exercises significant influence, but does not control, are accounted for using the equity method, whereby investment accounts are increased (decreased) for the Company’s proportionate share of income (losses), but investment accounts are not reduced below zero. The Company holds a 28.5% ownership investment, consisting of founders’ shares acquired at nominal cost, in HJLA. To date, HJLA has recorded cumulative losses. Since the Company’s investment is recorded at $0, the Company has not recorded its proportionate share of HJLA’s losses. If HJLA reports net income in future years, the Company will apply the equity method only after its share of HJLA’s net income equals its share of net losses previously incurred. Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, which range from 5 to 7 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized. Impairment of Long-lived Assets The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. FASB ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Quoted prices available in active markets for identical assets or liabilities trading in active markets. Level 2 Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. Financial instruments, including accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company’s other financial instruments include notes payable, the carrying value of which approximates fair value, as the notes bear terms and conditions comparable to market for obligations with similar terms and maturities. Derivative liabilities are accounted for at fair value on a recurring basis. The fair value of derivative liabilities as of December 31, 2018 and December 31, 2017, by level within the fair value hierarchy appears below: Description: Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liabilities - Preferred Stock Series A Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 541,990 Derivative liabilities - Preferred Stock Series B Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 60,551 Derivative liabilities - Convertible Debt Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 1,298,012 Derivative liabilities - Convertible Debt Embedded Conversion Feature December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 1,176,365 The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Derivative Liabilities Balance – January 1, 2017 $ 551,351 Issuance of derivative liabilities - common stock Series B warrants 57,283 Issuance of derivative liabilities - convertible debt warrants 1,268,177 Issuance of derivative liabilities - convertible debt conversion feature 2,349,560 Extinguishment of derivative liabilities - convertible debt conversion feature (1,175,668 ) Change in fair value of derivative liabilities 26,215 Balance - December 31, 2017 3,076,918 Issuance of derivative liabilities - convertible debt warrants 1,942,362 Issuance of derivative liabilities - convertible debt embedded conversion feature 3,652,588 Extinguishment of derivative liabilities upon debt modification (2,420,390 ) Change in fair value of derivative liabilities (191,656 ) Extinguishment of derivative liabilities upon conversion of debt (2,465,820 ) Reclassification of warrant derivatives to equity (3,594,002 ) Balance - December 31, 2018 $ - Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity under U.S. GAAP when determining the classification and measurement of its Series A and Series B Preferred Stock (together, the “Preferred Stock”). Preferred stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable preferred stock (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, preferred stock is classified as permanent equity. As of the issuance date, the carrying amount of the Preferred Stock was less than the redemption value. If the Company were to determine that redemption was probable, the carrying value would be increased by periodic accretions such that the carrying value would equal the redemption amount at the earliest redemption date. Such accretion would be recorded as a preferred stock dividend (see Note 12 to the Financial Statements – Temporary Equity). Derivative Liabilities Derivative financial instruments are recorded as a liability at fair value and are marked-to-market as of each balance sheet date. The change in fair value at each balance sheet date is recorded as a change in the fair value of derivative liabilities on the statement of operations for each reporting period. The fair value of the derivative liabilities was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The Company reassesses the classification of the financial instruments at each balance sheet date. If the classification changes as a result of events during the period, the financial instrument is marked to market and reclassified as of the date of the event that caused the reclassification. On June 4, 2018, in connection with the Company’s IPO, all of its previously issued convertible notes were converted and paid in full (as discussed in Note 8 to the Financial Statements - Convertible Notes and Convertible Note – Related Party), and the embedded conversion options and warrants no longer qualified as derivatives; accordingly, the derivative liabilities were remeasured to fair value on June 4, 2018 and the fair value of derivative liabilities of $3,594,002 was reclassified to additional paid in capital (see Fair Value of Financial Instruments, above). The Company recorded a gain and a loss on the change in fair value of derivative liabilities of $191,656 and $26,215 during the years ended December 31, 2018 and 2017, respectively. Convertible Notes The convertible notes payable discussed in Note 8 to the Financial Statements – Convertible Notes and Convertible Note – Related Party, had a conversion price that could be adjusted based on the Company’s stock price, which resulted in the conversion feature being recorded as a derivative liability and a debt discount. The debt discount was amortized to interest expense over the life of the respective note, using the effective interest method. On June 4, 2018, principal of $10,000 owed on the Convertible Notes was paid in cash, and all of the remaining principal and interest owed pursuant to the Convertible Notes were converted into common stock in connection with the Company’s IPO. The conversion of the Convertible Notes was deemed to be a debt extinguishment; accordingly, the warrant and embedded conversion option derivative liabilities were remeasured to fair value on June 4, 2018 and reclassified to additional paid in capital (See Derivative Liabilities, above). Net Loss per Share The Company computes basic and diluted loss per share by dividing net loss attributable to common stockholders by the weighted average number of common stock outstanding during the period. Net loss income attributable to common stockholders consists of net loss, adjusted for the convertible preferred stock deemed dividend resulting from the 8% cumulative dividend on the Preferred Stock and the beneficial conversion feature recorded in connection with the conversion of the Preferred Stock (see Note 12 to the Financial Statements – Temporary Equity). Basic and diluted net loss per common share are the same since the inclusion of common stock issuable pursuant to the exercise of warrants and options, plus the conversion of preferred stock or convertible notes, in the calculation of diluted net loss per common shares would have been anti-dilutive. The following table summarizes net loss attributable to common stockholders used in the calculation of basic and diluted loss per common share: For the Years Ended December 31, 2018 2017 Net loss $ (13,042,709 ) $ (7,791,469 ) Deemed dividend to Series A and B preferred stockholders (3,310,001 ) (459,917 ) Net loss attributable to common stockholders $ (16,352,710 ) $ (8,251,386 ) The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of December 31, 2018 and 2017: December 31, 2018 2017 Shares of common stock issuable upon conversion of preferred stock - 629,746 Shares of common stock issuable upon exercise of preferred stock warrants and the subsequent conversion of the preferred stock issued therewith - 50,285 Shares of common stock issuable upon the conversion of convertible debt - 229,208 Shares of common stock issuable upon exercise of warrants 3,780,571 371,216 Shares of common stock issuable upon exercise of options and restricted stock units 2,883,256 1,422,000 Potentially dilutive common stock equivalents excluded from diluted net loss per share 6,663,827 2,702,455 Revenue Recognition In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers - Principal versus Agent Considerations”, in April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing” and in May 9, 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606)”, or ASU 2016-12. This update provides clarifying guidance regarding the application of ASU No. 2014-09 - Revenue From Contracts with Customers which is not yet effective. These new standards provide for a single, principles-based model for revenue recognition that replaces the existing revenue recognition guidance. In July 2015, the FASB deferred the effective date of ASU 2014-09 until annual and interim periods beginning on or after December 15, 2017. It has replaced most existing revenue recognition guidance under U.S. GAAP. The ASU may be applied retrospectively to historical periods presented or as a cumulative-effect adjustment as of the date of adoption. The Company adopted Topic 606 using a modified retrospective approach and will be applied prospectively in the Company’s financial statements from January 1, 2018 forward. Revenues under Topic 606 are required to be recognized either at a “point in time” or “over time”, depending on the facts and circumstances of the arrangement, and will be evaluated using a five-step model. The adoption of Topic 606 did not have a material impact on the Company’s financial statements, at initial implementation nor will it have a material impact on an ongoing basis. The Company recognizes revenue when goods or services are transferred to customers in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. In determining when and how revenue is recognized from contracts with customers, the Company performs the following five-step analysis: (i) identification of contract with customer; (ii) determination of performance obligations; (iii) measurement of the transaction price; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The following table summarizes the Company’s revenue recognized in the accompanying statements of operations: For the Years Ended December 31, 2018 2017 Product sales $ - $ 184,800 Royalty income 116,152 137,711 Contract research - related party 70,400 99,600 Total Revenues $ 186,552 $ 422,111 Revenue from sales of products is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the product is shipped to the customer. Royalty revenue, which is based on resales of ProCol Vascular Bioprosthesis to third-parties, will be recorded when the third-party sale occurs and the performance obligation has been satisfied. Contract research and development revenue is recognized over time using an input model, based on labor hours incurred to perform the research services, since labor hours incurred over time is thought to best reflect the transfer of service. Information on Remaining Performance Obligations and Revenue Recognized from Past Performance Information about remaining performance obligations pertaining to contracts that have an original expected duration of one year or less is not disclosed. The transaction price allocated to remaining unsatisfied or partially unsatisfied performance obligations with an original expected duration exceeding one year was not material at September 30, 2018. Contract Balances The timing of our revenue recognition may differ from the timing of payment by our customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, deferred revenue is recorded until the performance obligations are satisfied. The Company had deferred revenue of $33,000 and $103,400 as of December 31, 2018 and 2017, respectively, related to cash received in advance for contract research and development services. The Company expects to satisfy its remaining performance obligations for contract research and development services and recognize the deferred revenue over the next twelve months. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and recognized over the period services are required to be provided in exchange for the award, usually the vesting period. Forfeitures of unvested stock options are recorded when they occur. Concentrations The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. There were aggregate uninsured cash balances of $2,490,645 at December 31, 2018. There were no cash balances in excess of federally insured amounts at December 31, 2017. During the year ended December 31, 2017, 44% of the Company’s revenues were from the sub-contract manufacture of product for LeMaitre Vascular, Inc. (“LeMaitre”), and 33% were from royalties earned from the sale of product by LeMaitre, with whom the Company entered a three-year Post-Acquisition Supply Agreement effective March 18, 2016. During the year ended December 31, 2018, 62% of the Company’s revenues were from royalties earned from the sale of product by LeMaitre. The three-year Post-Acquisition Supply Agreement from which the Company earns royalty from the sale of product by LeMaitre ends on March 18, 2019. The Company did not recognize any subcontract manufacturing revenues during the year ended December 31, 2018. During the years ended December 31, 2018 and 2017, 38% and 24%, respectively, of the Company’s revenues were earned from contract research and development services performed for HJLA. Subsequent Events The Company evaluated events that have occurred after the balance sheet date through the date the financial statements were issued. Based upon the evaluation and transactions, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed in Note 17 to the Financial Statements - Subsequent Events. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018. As a result of the new standard, all of our leases greater than one year in duration will be recognized in our Balance Sheets as both operating lease liabilities and right-of-use assets upon adoption of the standard. We will adopt the standard using the prospective approach. Upon adoption, we expect to record approximately $1.1 million in right-of-use assets and operating lease liabilities in our Balance Sheets. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments (Topic 230)” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. ASU 2016-15 requires adoption on a retrospective basis unless it is impracticable to apply, in which case the Company would be required to apply the amendments prospectively as of the earliest date practicable. The adoption of ASU 2016-15 did not have a material impact on the Company’s financial statements. In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718); Scope of Modification Accounting. The amendments in this ASU provide guidance that clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. If the fair value, vesting conditions or classification of the award changes, modification accounting will apply. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2017-09 did not have a material impact on the Company’s financial statements. On June 20, 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting, which simplifies accounting for share-based payment transactions resulting for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard was adopted effective April 1, 2018, using the modified retrospective approach; however, the Company did not identify or record any adjustments to the opening balance of retained earnings on adoption. The new standard did not have a material impact on the Company’s financial statements.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 – Property and Equipment As of December 31, 2018 and 2017, property and equipment consist of the following: December 31, 2018 2017 Lab equipment $ 94,905 $ 120,861 Furniture and fixtures 93,417 93,417 Computer software and equipment 26,830 14,409 Leasehold improvements 158,092 158,092 373,244 386,779 Less: accumulated depreciation (347,091 ) (362,936 ) Property and equipment, net $ 26,153 $ 23,843 During the year ended December 31, 2017, the Company wrote off $25,956 of fully depreciated lab equipment that was no longer in use. Depreciation and amortization expense amounted to $10,112 and $15,905 for the years ended December 31, 2018 and 2017, respectively. Depreciation and amortization expense is reflected in general and administrative expenses in the accompanying statements of operations.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 6 – Intangible Assets On May 10, 2013, the Company purchased a patent related to heart valve bioprosthesis technology. The patent expires on July 9, 2027. On April 1, 2016, the Company acquired the exclusive rights to develop and manufacture a derma filler product for which HJLA holds a patent, for aggregate consideration of $445,200. (See Note 11 to the Financial Statements – Commitments and Contingencies - Development and Manufacturing Agreement As of December 31, 2018 and 2017, the Company’s intangible assets consisted of the following: December 31, 2018 2017 Patent $ 1,100,000 $ 1,100,000 Right to develop and manufacture - 445,200 1,100,000 1,545,200 Less: accumulated amortization (433,533 ) (435,790 ) Total $ 666,467 $ 1,109,410 Amortization expense charged to operations for the years ended December 31, 2018 and 2017 was $123,308 and $123,308, respectively, and is reflected in general and administrative expense in the accompanying statements of operations. The estimated future amortization of Patent is as follows: For the Years Ended December 31, Patent 2019 $ 77,647 2020 77,647 2021 77,647 2022 77,647 2023 77,647 Thereafter 278,232 $ 666,467 The remaining amortization period of the Patent is 8.5 years as of December 31, 2018 and has no residual value.

Accrued Expenses and Accrued In

Accrued Expenses and Accrued Interest - Related Party	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued Expenses and Accrued Interest - Related Party	Note 7 – Accrued Expenses and Accrued Interest – Related Party As of December 31, 2018 and 2017, accrued expenses consist of the following: December 31, 2018 2017 Accrued compensation costs $ 288,549 $ 556,118 Accrued professional fees 55,300 235,654 Deferred rent 22,473 4,978 Accrued interest - 101,050 Accrued franchise taxes 26,985 - Accrued research and development 17,064 - Other accrued expenses 2,500 5,794 Accrued expenses $ 412,871 $ 903,594 Included in accrued compensation costs in the table above is accrued severance expense of $166,154 pursuant to the terms of the employment agreement for the Company’s prior Chief Financial Officer, who was terminated effective July 20, 2018. Accrued interest - related parties consisted of accrued interest on notes payable to the majority stockholder and to Leman Cardiovascular S.A. (see Note 9 to the Financial Statements - Notes Payable and Note Payable – Related Party) totaling, in the aggregate, $0 and $20,558 as of December 31, 2018 and 2017, respectively.

Convertible Notes and Convertib

Convertible Notes and Convertible Note - Related Party	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Convertible Notes and Convertible Note - Related Party	Note 8 - Convertible Notes and Convertible Note – Related Party Convertible Notes During the period from June 15, 2017 through December 7, 2017, the Company issued senior secured convertible promissory notes aggregating $2,750,500. The Company incurred cash offering costs of $186,100 (including $129,030 of placement agent fees) resulting in net cash proceeds of $2,564,400. The notes, as amended on December 29, 2017 (the “2017 Convertible Notes”), matured on February 28, 2018, and bore interest at 15% per annum. The 2017 Convertible Notes included warrants exercisable for the number of shares of common stock equal to 75% of the total shares issuable upon the conversion of the related 2017 Convertible Note, at a price equal to the lesser of (i) $14.40 per share or (ii) 120% of the 2017 Conversion Price. In connection with the sale of the 2017 Convertible Notes, the Company issued five-year warrants to the placement agent for the financing for the purchase of 15,339 shares of common stock at an exercise price of $15.84 per share (see Note 14 to the Financial Statements – Warrants). The fair value of the conversion option and warrants issued in connection with the 2017 Convertible Notes had an issuance date fair value of $1,175,668 and $397,211, respectively, and the aggregate of $1,572,879 was recorded as a debt discount and a derivative liability. From January 5, 2018 through January 16, 2018, the Company issued senior secured convertible notes (the “2018 Convertible Notes”) in the aggregate amount of $2,897,500. The Company incurred cash offering costs of $293,750 (including $289,750 of placement agent fees) resulting in net cash proceeds of $2,603,750. The 2018 Convertible Notes bore interest at 15% per annum and were due on February 28, 2018 (the “Maturity Date”). The 2018 Convertible Notes include five-year warrants exercisable for the number of common stock equal to 50% of the total shares issuable upon the conversion of the 2018 Convertible Note, at a price equal to the lesser of (i) $14.40 per share or (ii) 120% of the 2018 Conversion price. In connection with the sale of the 2018 Convertible Notes, the Company agreed to issue a five-year warrant to the placement agent for the financing for the purchase of 24,146 shares of common stock, exercisable at a price equal to the 110% of the greater of (i) the price at which the securities are issued, or (ii) the exercise price of the debt holder warrants. The fair value of the conversion option and the warrants issued in connection with the 2018 Convertible Notes had an issuance date fair value of $1,239,510 and $1,046,763, respectively, and the aggregate of $2,286,273 was recorded as a debt discount and a derivative liability. The 2017 Convertible Notes and the 2018 Convertible Notes are referred to herein together as the “Convertible Notes”. On February 28, 2018, the Convertible Notes were amended such that the maturity date was extended to May 15, 2018, the 2017 Convertible Note warrants became exercisable for the number of shares of common stock equal to 100% of the total shares issuable upon the conversion of the 2017 Convertible Notes and the 2018 Convertible Note Warrants become exercisable for the number of shares of common stock equal to 75% of the total shares issuable upon the conversion on the 2018 Convertible Notes. The amendment of the Convertible Notes was deemed to be a debt extinguishment and, as a result, during the years ended December 31, 2018, the Company recognized a $1,524,791 gain on extinguishment of convertible notes payable within the accompanying statement of operations consisting of the extinguishment of $2,420,390 of derivative liabilities associated with the embedded conversion option of the extinguished Convertible Notes, partially offset by the issue date fair value of additional warrants issued (deemed to be a derivative liability) in the amount of $895,599. Additionally, the embedded conversion option within the re-issued Convertible Notes was deemed to be a derivative liability and the relative fair value was recorded as a discount in the amount of $2,413,079. On June 4, 2018, principal and interest of $10,000 and $267, respectively, were paid in cash and all remaining principal and accrued interest balances of the Convertible Notes were automatically converted into 1,650,537 shares of common stock upon the closing of the IPO at a conversion price of $3.50 per share. The conversion of the Convertible Notes was deemed to be a debt extinguishment and, as a result, the Company recognized a $43,474 loss on extinguishment of convertible notes payable within the accompanying statement of operations consisting of the fair value of the common stock issued upon the conversion of the Convertible Notes of $8,252,685, less the extinguishment of $5,743,391 of principal and interest converted and $2,465,820 of derivative liabilities associated with the embedded conversion option of the extinguished Convertible Notes. Interest expense incurred in connection with the Convertible Notes was $305,452 and $172,800 during the years ended December 31, 2018 and 2017, respectively. Convertible Note – Related Party On June 30, 2015, the Company entered into a loan agreement with its then-majority (78%) common stock shareholder, (the “2015 Note”). The 2015 Note had a maximum borrowing capacity of $2,200,000 and bore interest at 3% per annum. On April 1, 2016, the 2015 Note was amended such that the 2015 Note became convertible into shares of common stock at the option of the lender at a conversion price of $10.00 per share. During the years ended December 31, 2018 and 2017, the Company borrowed $0 and $311,000, respectively, under the 2015 Note. On April 26, 2018, the outstanding principal balance and accrued interest of the 2015 Note was converted into 120,405 shares of common stock at a conversion price of $4.30 per share. The Company incurred interest expense related to the 2015 Note of $4,613 and $13,886 during the years ended December 31, 2018 and 2017, respectively.

Notes Payable and Note Payable

Notes Payable and Note Payable - Related Party	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Notes Payable and Note Payable - Related Party	Note 9 - Notes Payable and Note Payable – Related Party Notes Payable During December 2017, the Company borrowed an aggregate of $275,000 pursuant to two promissory notes, which bore interest at 10% per annum. The notes were repaid in full during January 2018. The Company incurred interest expense of $958 and $1,188 during the year ended December 31, 2018 and 2017, respectively in connection with these notes. On May 15, 2018, the Company received aggregate proceeds of $722,500 in exchange for certain promissory notes (the “May Notes”) in the aggregate principal amount of $850,000 and 55,000 shares of the Company’s common stock, net of commissions of $27,500. The $27,500 commission and the original issue discount of $100,000 were recorded as debt discount, and the relative fair value of the common stock issued in connection with the May Notes of $228,966 was recorded as a debt discount with a corresponding credit to additional paid-in capital. The May Notes bore interest between 0-10% per annum and were repaid in full upon the consummation of the IPO on June 4, 2018. The Company incurred $4,911 of interest expense during the year ended December 31, 2018 in connection with the May Notes. Note Payable – Related Party The Company had a note payable to a related party (the “Related Party Note”), of which the Company’s Former President and Vice President of Operations were officers, and of which a member of the Company’s Board of Directors is a shareholder. The Related Party Note, as amended, bore interest at 6% per annum and matured on May 10, 2018. On April 26, 2018, the outstanding principal balance and accrued interest of the Related Party Note was amended such that the note became convertible into common stock at a conversion price of $4.30, and on the same day, principal and interest in the aggregate of $150,553 due in connection with the Related Party Note was converted into 35,012 shares of common stock. The Company incurred interest expense of $4,078 and $21,283 during the years ended December 31, 2018 and 2017, respectively, in connection with the Related Party Note.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 10 – Income Taxes The following summarizes the Company’s income tax provision (benefit): For the Years Ended December 31, 2018 2017 Federal: Current $ - $ - Deferred (1,710,997 ) (138,931 ) State and local: Current - - Deferred (570,332 ) (479,833 ) (2,281,329 ) (618,764 ) Change in valuation allowance 2,281,329 618,764 Income tax provision (benefit) $ - $ - The reconciliation between the U.S. statutory federal income tax rate and the Company’s effective tax rate for the year’s ended December 31, 2018 and 2017 is as follows: For the Years Ended December 31, 2018 2017 Tax benefit at federal statutory rate (21.0 )% (34.0 )% State taxes, net of federal benefit (7.0 )% (6.0 )% Permanent differences 11.4 % 9.4 % True up adjustments (0.9 )% 1.3 % Effect of change in tax rate 0.0 % 21.3 % Change in valuation allowance 17.5 % 7.9 % Effective income tax rate (0.0 )% (0.0 )% Significant components of the Company’s deferred tax assets at December 31, 2018 and 2017 are as follows: December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 5,298,599 $ 3,122,308 Research and development credit carryforwards 185,680 185,680 Intangible assets 152,109 48,629 Property and equipment 30,957 34,974 Accrued salaries - 106,400 Stock-based compensation 526,945 419,868 Deferred rent 6,292 1,394 Impairment loss 136,612 136,612 Total gross deferred tax assets 6,337,194 4,055,865 Less: valuation allowance (6,337,194 ) (4,055,865 ) Total $ - $ - Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes to offset its post-change income taxes may be limited. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carry forwards are subject to annual limitations due to a greater than 50% ownership change in 2018. At December 31, 2018 and 2017, the Company had post-ownership change net operating loss carryforwards for federal and state income tax purposes of approximately $17.4 million and $11.1 million, respectively. Pre-2018 federal and state net operating loss (“NOL”) carryovers may be carried forward for twenty years and begin to expire in 2026. Under the Tax Act, post-2017 federal NOLs can be carried forward indefinitely and the annual limit of deduction equals 80% of taxable income. However, to the extent the Company utilizes its NOL carryforwards in the future, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities of the future period tax return in which the attribute is utilized. The Company also has federal research and development tax credit carryforwards of approximately $0.2 million which begin to expire in 2027. The Company files income tax returns in the U.S. federal jurisdiction as well as California and local jurisdictions and is subject to examination by those taxing authorities. The Company’s federal, state and local income taxes for the years beginning in 2015 remain subject to examination. No tax audits were initiated during 2018 or 2017. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2018 and 2017. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statements of operations. New tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”, was enacted on December 22, 2017, which, among things, reduced the United States corporate income tax rate from 35% to 21%. Pursuant to ASC 740, Accounting for Income Taxes, the Company was required to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions of the Tax Act is for tax years beginning after December 31, 2017. The change in tax law required the Company to remeasure existing net deferred tax assets using the lower rate in the period of enactment, resulting in a reduction of the deferred tax asset balance as of December 31, 2017 by $1.7 million. Due to the Company’s full valuation allowance position, there was no net impact on the Company’s income tax provision at December 31, 2017 as the reduction in the deferred tax asset balance was fully offset by a corresponding decrease in the valuation allowance.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 – Commitments and Contingencies Litigations Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. On September 25, 2018, ATSCO, Inc., filed a complaint with the Superior Court seeking payment of $809,520 plus legal costs for disputed invoices to the Company dated from 2015 to June 30, 2018. The Company had entered into a Services and Material Supply Agreement (“Agreement”), dated March 4, 2016 to supply porcine and bovine tissue. The Company is disputing the amount owed and that the Agreement called for a fixed monthly fee regardless of tissue delivered. The Company believes it has numerous defenses and rights of setoff including without limitation: that ATSCO had an obligation to mitigate the fees when they were not delivering tissues and not incurring any costs; $173,400 of the amount that ATSCO is seeking are for invoices to Hancock Jaffe Laboratory Aesthetics, Inc. (in which the Company owns a minority interest of 28.0% as described in Note 4 to the Financial Statements – Significant Accounting Policies - Investments On October 8, 2018, Gusrae Kaplan Nusbaum PLLC (“Gusrae”) filed a complaint with the Supreme Court of the State of New York seeking payment of $178,926 plus interest and legal costs for invoices to the Company dated from November 2016 to December 2017. In July 2016, the Company retained Gusrae to represent the Company in connection with certain specific matters. The Company believes that Gusrae has not applied all of the payments made by the Company along with billing irregularities and errors and is disputing the amount owed. The Company recorded the disputed invoices in accounts payable and as of December 31, 2018, the Company has fully accrued for the outstanding claim against the Company. The Company has been contacted by an individual that claims to be owed a fee for introducing the Company to Alexander Capital. The Company has conducted its own factual investigation and legal analysis and believes that the claim is without merit. The individual has threatened to file a lawsuit, and in the event that a lawsuit is filed, the Company would have numerous defenses including without limitation that the individual was unlicensed to provide the services he alleges he provided. Property Lease Obligation On or about July 1, 2010, the Company’s seven-year lease for 14,507 square foot industrial building located in Orange County, California became effective. The lease required a $26,113 security deposit and the prepayment of the first month’s rent at the inception of the lease. Monthly rent payments under the lease at the inception of the lease were $21,761 and payments increase by 5% every 24 months. Payments under the lease also include real estate taxes not to exceed $7,254 per month. The lease expired on June 30, 2017. The Company rented the building on a month-to-month basis from July 1, 2017 through September 30, 2017. On September 20, 2017, the Company entered into an agreement to renew the lease effective October 1, 2017. The lease renewal has a five-year term. Rent expense pursuant to the lease is $26,838 per month for the first year and increases by 3% on each anniversary of the lease inception date. As of December 31, 2018, remaining future minimum lease payments under the lease are $1,304,847. On May 1, 2016, the Company’s entered into a one-year lease of an apartment located in Irvine, California for the chairman of the Company’s board of directors, who resides in Switzerland. The lease required a $3,720 security deposit and the monthly rent payments under the lease were $1,860. The lease expired on April 30, 2017 and the Company is currently renting the apartment on a month-to-month basis at $2,010 per month. Future minimum lease payments under the Company’s operating leases are as follows: For The Years Ending December 31, Amount 2019 $ 334,203 2020 344,229 2021 354,561 2022 271,854 Total 1,304,847 The Company recognizes rent expense on a straight-line basis over the term of the respective lease. Differences between the straight-line rent expenses and rent payments are included in accrued expenses on the accompanying balance sheets. Rent expense for the years ended December 31, 2018 and 2017 was $348,227 and $418,358, respectively. Development and Manufacturing Agreement On April 1, 2016, the Company entered into a development and manufacturing agreement with HJLA, pursuant to which: (1) the Company paid $445,200 for the exclusive right to provide development and manufacturing services to HJLA for a period of ten years (see Note 6 to the Financial Statements – Intangible Assets), and (2) the Company has the right to purchase up to 484,358 shares of common stock of HJLA at $8.66 per share for an aggregate purchase price of $4,194,540 through April 1, 2021. Through the date these financial statements were available to be issued, no shares were purchased pursuant to this agreement. Employment Agreements Chief Executive Officer On March 20, 2018, the Company entered into an Amendment to Employment Agreement (the “Employment Amendment”) with the Company’s then Chief Executive Officer (the “Old CEO”), pursuant to which the Old CEO was removed from the position of Chief Executive Officer of the Company and was appointed to serve as the Company’s Chief Medical Officer Outside of the United States. The Employment Amendment represented a change in position only; all other terms and conditions of the Old CEO’s Employment Agreement with the Company remained in effect. Further, on March 20, 2018, the employment of the Company’s then Co-Chief Executive Officer was terminated without cause, and the Company entered into an Employment Agreement (the “New CEO Agreement”) with Robert Berman (the “New CEO”) under which he serves as the Company’s Chief Executive Officer. The New CEO Agreement provides for an annual base salary of $400,000 as well as standard employee insurance and other benefits. Pursuant to the New CEO Agreement, the New CEO is eligible for annual salary increases at the discretion of the Company’s Board of Directors as well as annual bonus payments of up to 50% of base salary, as determined by the Compensation Committee of the Board of Directors. The New CEO Agreement provides for severance payments equal to six months of base salary in the event of termination without cause, severance payments equal to one year of base salary if such termination occurs on or after the two-year anniversary of the effective date of the New CEO Agreement and severance payments equal to two years of base salary if such termination occurs within 24 months of a change in control of the Company. In addition, in connection with the New CEO Agreement, the New CEO received an option for the purchase of up to 6.5% of the Company’s common stock on a fully-diluted basis as of the date of the IPO. The New CEO’s employment with the Company is “at-will”, and may be terminated at any time, with or without cause and with or without notice by either the New CEO or the Company. Chief Financial Officer On July 16, 2018, the Company entered into an employment agreement with Mr. Robert Rankin (the “CFO Employment Agreement”) under which he serves as the Company’s Chief Financial Officer. The CFO Employment Agreement provides for an annual base salary of $250,000 as well as standard employee insurance and other benefits. Pursuant to the CFO Employment Agreement, Mr. Rankin is eligible for annual salary increases at the discretion of the Company’s Board of Directors as well as an annual year-end discretionary bonus of up to 30% of his base salary, subject to the achievement of key performance indicators, as determined by the Board and the Chief Executive Officer of the Company in their sole discretion. The CFO Employment Agreement provides for severance payments in the event of termination without Cause or he resigns for Good Reason, as defined in the CFO Agreement, equal to three months of base salary for each year that he has been employed by the Company at the time of termination, up to a total of one year of his base salary, provided, that if such termination results from a Change of Control, as defined in the CFO Employment Agreement, Mr. Rankin’s severance will not be less than six months of his base salary. In addition, in connection with the CFO Employment Agreement, Mr. Rankin received an initial equity grant of an option (the “CFO Option”) to purchase up to 150,000 shares of the Company’s common stock. 50,000 of the shares will vest on the first anniversary of Mr. Rankin’s employment with the Company, and the remaining 100,000 shares will vest on a quarterly basis over the following two-year period, provided that all unvested shares will immediately vest upon a Change of Control. The CFO Option will have an exercise price per share equal to $2.98, the last reported sale price of the Company’s common stock on the Nasdaq Capital Market on July 16, 2018, the date of the grant. Mr. Rankin’s employment with the Company is “at-will”, and may be terminated at any time, with or without cause and with or without notice by either Mr. Rankin or the Company. R&D Agreement On October 2, 2018, The Company entered into an Agreement with the Texas Heart Institute for the development of the Company’s CoreoGraft product to be used for coronary artery bypass surgery. The Company estimates the initial feasibility study will cost approximately $200,000. The agreement will terminate on August 31, 2019 and may be extended by mutual consent.

Temporary Equity

Temporary Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Temporary Equity	Note 12 – Temporary Equity On March 1, 2017, the Company filed a second amended and restated certificate of incorporation, to increase the number of the Company’s authorized shares of preferred stock to 6,000,000, to designate 1,300,000 shares of the Company’s authorized preferred stock as Series A preferred Stock, or Series A preferred stock, and set forth the rights, preferences and privileges of the Company’s Series A preferred stock. On June 8, 2017, the Company filed a third amended and restated certificate of incorporation to revise certain protective voting provisions afforded to the holders of the Company’s preferred stock. On the same date, the Company filed a certificate of designation, preferences, rights and limitations of Series B convertible preferred stock, to designate 2,000,000 shares of the Company’s authorized preferred stock as Convertible Series B Preferred Stock, or Series B preferred stock, and set forth the rights, preferences and privileges of the Company’s Series B preferred stock. The Company’s Preferred Stock had certain redemption rights that were considered by the Company to be outside of the Company’s control. Accordingly, the Series A Preferred Stock and Series B Preferred Stock are presented as temporary equity on the Company’s balance sheets for December 31, 2017. The Series A and Series B Preferred Stock were convertible at the option of the holder at a conversion price of $10.00 and $12.00 per share, respectively, which was reduced to $4.30 and $4.50 per share, respectively, if the conversion resulted from a mandatory IPO conversion. On June 4, 2018, all Series A and Series B Preferred Stock and dividends in arrears of $911,151 and $107,556, respectively, were mandatorily converted into 1,743,231 shares of common stock, upon the completion of the IPO (see Note 2 to the Financial Statements – Initial Public Offering). In connection with the mandatory conversion of the Preferred Stock, the Company recorded a deemed dividend of $3,087,591 equal to the number of additional shares of common stock issued upon conversion of the Preferred Stock resulting from the reduction in the conversion price upon the mandatory IPO conversion, multiplied times the fair value of the common stock on the commitment date.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Common Stock	Note 13 – Common Stock On October 31, 2017, our Board of Directors approved a 1 for 2 reverse stock split of the Company’s common stock, which was effected on December 14, 2017. Per share and share amounts presented herein have been adjusted for all periods presented to give retroactive effect to the aforementioned stock splits. The Company completed the IPO via an issuance of common stock and warrants on June 4, 2018 (see Note 2 to the Financial Statements - Initial Public Offering). In connection with the IPO, on June 1, 2018, the Company filed an Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware and adopted the Amended and Restated Bylaws (the “Restated Bylaws”). The Company’s Board of Directors and stockholders previously approved the Restated Certificate and the Restated Bylaws to be effective immediately prior to the closing of the IPO. Pursuant to the Restated Certificate, the Company is authorized to issue an aggregate of 60,000,000 shares of stock, of which 50,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock. On April 26, 2018, the Company issued 44,444 shares of common stock with an aggregate fair value of $200,000, in satisfaction of deferred salary to its Chief Medical Officer Outside the United States. On June 18, 2018, the Company issued 30,000 shares of common stock with an aggregate fair value of $90,000, in satisfaction of fees payable to its Medical Advisory Board and granted 160,000 shares of immediately vested common stock with an aggregate fair value of $798,400 to certain consultants. On June 18, 2018, the Company also granted 20,000 shares of common stock to a consultant with a fair value of $99,800, which per the Consulting Agreement with the consultant will vest monthly over next twelve months. However, the Company terminated the Consulting Agreement with that consultant as of December 26, 2018. Per the Agreement, the 6,137 unvested shares are to be returned to the Company by the consultant. The Company recognized $69,176 of stock-based compensation expense related to the vested shares of common stock in 2018. On May 1, 2018, Dr Broennimann entered into a Service Agreement to perform the role of Chief Medical Officer (Out of US) for a fee of $15,000 monthly provided that the Company may, at its sole option, elect to pay 25% of the monthly fee in company common stock with the number of common stock determined by dividing the 25% of the monthly fee by the closing price of the Company’s common stock on the 2 nd

Warrants

Warrants	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Warrants	Note 14 - Warrants During the years ended December 31, 2018 and 2017, the Company issued five-year warrants in connection with the issuance of the Convertible Notes (see Note 8 to the Financial Statements – Convertible Notes and Convertible Note – Related Party) for the purchase of 1,441,298 shares of common stock and issued five-year warrants for the purchase of 138,392 shares of common stock to the placement agents. In connection with the IPO, the exercise price of the warrants issued to investors and the placement agent in connection with the Convertible Notes became fixed at $4.20 per share and $4.62 per share, respectively, pursuant to the terms of the warrants. On June 4, 2018, the Company issued five-year warrants for the purchase of 1,725,000 shares of common stock at an exercise price of $6.00 per share to purchasers of Units in the IPO and issued five-year warrants for the purchase of 75,000 shares of common stock at an exercise price of $6.25 to the underwriter for the IPO. Further, in connection with the IPO, warrants for the purchase of 100,570 shares of Series A Preferred Stock were amended such that they became exercisable for the purchase of 116,912 shares of common stock at an exercise price of $4.30 per share. The amendment was accounted for as a modification of a stock award. The Company determined that there was no incremental increase in the fair value for the amendment of the award and accordingly there was no charge to the statement of operations for the years ended December 31, 2018. On June 18, 2018, the Company issued five-year warrants for the purchase 100,000 shares of common stock to certain consultants. The warrants vested immediately, were exercisable at $4.99 per share and had a grant date fair value of $179,000 using the Black-Scholes pricing model, with the following assumptions used: stock price of $4.93, risk free interest rate of 2.67-2.80%, expected term of 3-5 years, volatility of 42.6% and an annual rate of quarterly dividends of 0%. A summary of warrant activity during the years ended December 31, 2018 and 2017 is presented below: Series A Preferred Stock Common Stock Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life in Years Intrinsic Value Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life in Years Intrinsic Value Outstanding, January 1, 2017 100,570 $ 5.00 416,666 12.00 Issued [1] 204,550 12.00 Exercised Cancelled (250,000 ) Outstanding, January 1, 2018 100,570 $ 5.00 371,216 $ 12.00 Issued - - 3,292,443 6.09 Exercised - - - - Cancelled - - - - Amendment of placement agent warrants [2] (100,570 ) 5.00 116,912 4.30 Outstanding, December 31, 2018 - $ - - $ - 3,780,571 $ 5.48 [3] 4.1 $ - Exercisable, December 31, 2018 - $ - - $ - 3,780,571 $ 5.48 4.1 $ - [1] Warrants granted in 2017 consist of Series B warrants for purchase of 17,303 shares, convertible note debt holder warrants for purchase of 171,908 shares and convertible note placement agent warrants for purchase of 15,339 shares of common stock. [2] In connection with the IPO, placement agent warrants for the purchase of Series A Preferred Stock were amended such that the warrants became exercisable for the number of common stock that would have been issued upon the exercise of the Series A warrant and subsequent conversion to common stock upon the consummation of the IPO. The exercise price was amended to the price equal to the total proceeds that would have been required upon the exercise of the original warrant, divided by the amended number of warrant shares. The amendment was accounted for as a modification of a stock award. The Company determined that there was no incremental increase in the fair value for the amendment of the award and accordingly there was no charge to the statement of operations for the years ended December 31, 2018. [3] Pursuant to the terms of the warrant, the exercise price of the warrants issued to investors and the placement agent in connection with the sale of the Convertible Notes became fixed at $4.20 per share and $4.62 per share, respectively, at the date of the IPO, based upon the price of stock issued in the IPO. A summary of outstanding and exercisable warrants as of December 31, 2018 is presented below: Warrants Outstanding Warrants Exercisable Exercise Price Exercisable Into Outstanding Number of Warrants Weighted Average Remaining Life in Years Exercisable Number of Warrants $ 12.00 Common Stock 183,969 4.5 183,969 $ 6.25 Common Stock 75,000 4.4 75,000 $ 6.00 Common Stock 1,725,000 4.4 1,725,000 $ 4.99 Common Stock 100,000 4.5 100,000 $ 4.62 Common Stock 138,392 3.9 138,392 $ 4.30 Common Stock 116,912 2.1 116,912 $ 4.20 Common Stock 1,441,298 3.8 1,441,298 3,780,571 3,780,571

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Based Compensation	Note 15 – Stock Based Compensation Omnibus Incentive Plan On November 21, 2016, the board of directors approved the Company’s 2016 Omnibus Incentive Plan, which enables the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, other share based awards and cash awards to associates, directors, consultants, and advisors of the Company and its affiliates, and to improve the ability of the Company to attract, retain, and motivate individuals upon whom the Company’s sustained growth and financial success depend, by providing such persons with an opportunity to acquire or increase their proprietary interest in the Company. Stock options granted under the 2016 Plan may be non-qualified stock options or incentive stock options, within the meaning of Section 422(b) of the Internal Revenue Code of 1986, except that stock options granted to outside directors and any consultants or advisers providing services to the Company or an affiliate shall in all cases be non-qualified stock options. The option price must be at least 100% of the fair market value on the date of grant and if issued to a 10% or greater shareholder must be 110% of the fair market value on the date of the grant. The 2016 Plan is to be administered by the Board, which shall have discretion over the awards and grants thereunder. No awards may be issued after November 21, 2026. On December 11, 2017 the board of directors approved an amendment to the 2016 Omnibus Incentive Plan, whereby the number of common shares reserved for issuance under the plan was increased from 1,650,000 to 2,500,000. On April 26, 2018, our board of directors and our stockholders adopted and approved the Amended and Restated 2016 Omnibus Incentive Plan (the “2016 Plan”), whereby the number of common shares reserved for issuance under the plan was increased from 2,500,000 to 4,500,000, plus an annual increase on each anniversary of April 26, 2018 equal to 3% of the total issued and outstanding shares of our common stock as of such anniversary (or such lesser number of shares as may be determined by our board of directors). Stock Options On June 18, 2018, the Company granted non-qualified stock options for the purchase of 80,000 shares of common stock at an exercise price of $4.93 to members of its Medical Advisory Board. The options have a ten-year term and vest monthly over two years. The options had grant date fair value of $2.21 per share for an aggregate grant date fair value of $176,800, using the Black Scholes method with the following assumptions used: stock price of $4.93, risk-free interest rate of 2.85%, volatility of 42.6%, annual rate of quarterly dividends of 0%, and a contractual term of six years. On July 16, 2018, in connection with the CFO Employment Agreement, the Company granted non-qualified stock options for the purchase of 150,000 shares of common stock at an exercise price of $2.98 to its CFO, Mr. Rankin. The options have a ten-year term and 50,000 of the shares will vest on the first anniversary of Mr. Rankin’s employment with the Company, and the remaining 100,000 shares will vest on a quarterly basis over the following two-year period. The options had grant date fair value of $1.10 per share for an aggregate grant date fair value of $165,000, using the Black Scholes method with the following assumptions used: stock price of $2.98, risk-free interest rate of 2.76%, volatility of 35.6%, annual rate of quarterly dividends of 0%, and a contractual term of 5.3 years. On September 24, 2018, the Board of Directors of the Company approved the grant of a ten-year option to purchase an aggregate of 1,080,207 shares of the Company’s common stock at an exercise price of $4.99 per share (the “Option”) to its CEO, Robert Berman, which Option was issued pursuant to the terms of that certain employment agreement, dated March 30, 2018 (the “Effective Date”), between Mr. Berman and the Company (the “Employment Agreement”). The grant of the Option was in fulfillment of the express terms of the previously agreed to Employment Agreement. The Employment Agreement provides that Mr. Berman is entitled to receive an equity grant of an option to purchase up to 6.5% of the Company’s common stock outstanding on a fully diluted basis at the closing of the IPO. The shares subject to the Option will vest over a period of 2 years, with 1/5th of the shares subject to the Option having vested on the Effective Date (the “Initial Vesting”) and the remaining shares vesting in substantially equal monthly installments during the twenty-four (24) month period following the Effective Date and ending March 30, 2020. The Option had grant date fair value of $0.47 per share for an aggregate grant date fair value of $507,697, using the Black-Scholes method with the following assumptions used: stock price of $4.99, risk-free interest rate of 2.97%, volatility of 35.3%, annual rate of quarterly dividends of 0%, and a contractual term of 5.2 years. On October 1, 2018, Robert Anderson, Robert Doyle and Steven Girgenti (“Resigning Directors”) resigned as Directors of our Board. Effective upon their resignation, each of the Resigning Directors received a grant of 10,000 options to purchase shares of our common stock at an exercise price of $2.90, the closing price of our common stock on October 1, 2018. All of these options were vested in full as of the date of grant. The Option had grant date fair value of $0.50 per share for an aggregate grant date fair value of $15,000, using the Black-Scholes method with the following assumptions used: stock price of $1.97, risk-free interest rate of 2.89%, volatility of 36.1%, annual rate of quarterly dividends of 0%, and a contractual term of 5.5 years. Per the Amended and Restated 2016 Omnibus Incentive Plan, the options that were awarded and had vested to the Resigning Directors prior to their resignation would have to be exercised within 90 days of their resignation date or be forfeited. As part of their resignation agreement, all options granted to the Resigning Directors before their resignation date were modified such that they can be exercised by the Resigning Directors for a 10 year period from their original issuance dates. These options are treated as a modification and valued in accordance with FASB ASC Topic 718. The 40,000 options to purchase shares of our common stock issued to each of the Resigning Directors in 2017 at an exercise price of $12.00 per share were valued at $.10 per share as of the date of the modification for an aggregate grant date fair value of $12,000, using the Black-Scholes method with the following assumptions used: stock price of $2.90, risk-free interest rate of 2.96%, volatility of 36.1%, annual rate of quarterly dividends of 0%, and a contractual term of 5.0 years. The 3,000 options to purchase shares of our common stock issued to each of our former directors Robert Doyle and Robert Anderson in 2017 at an exercise price of $7.00 per share were valued at $.32 per share as of the date of the modification for an aggregate grant date fair value of $1,920 using the Black-Scholes method with the following assumptions used: stock price of $2.90, risk-free interest rate of 2.96%, volatility of 36.1%, annual rate of quarterly dividends of 0%, and a contractual term of 5.0 years. Under the Company’s A summary of the option activity during the years ended December 31, 2018 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2018 1,422,000 $ 10.16 Granted 1,520,207 4.46 Forfeited (146,500 ) 10.00 Outstanding, December 31, 2018 2,795,707 $ 7.07 9.0 $ - Exercisable, December 31, 2018 1,865,604 $ 8.50 8.4 $ - A summary of outstanding and exercisable options and Restricted Stock units as of December 31, 2018 is presented below: Options Outstanding Options Exercisable Exercise Price Exercisable Into Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $ 12.00 Common Stock 120,000 8.7 120,000 $ 10.00 Common Stock 1,149,500 7.8 1,149,500 $ 7.00 Common Stock 6,000 8.9 6,000 $ 4.99 Common Stock 1,080,207 9.7 540,104 $ 4.93 Common Stock 80,000 9.5 20,000 $ 2.98 Common Stock 150,000 9.5 - $ 2.90 Common Stock 30,000 9.9 30,000 $ 2.57 Common Stock 180,000 9.9 - Total 2,795,707 1,865,604 The Company recognized stock-based compensation related to stock options of $864,626 and $801,624 during the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, there was $758,012 of unrecognized stock-based compensation expense related to outstanding stock options that will be recognized over the weighted average remaining vesting period of 1.6 years. The employment of William Abbott, our prior Chief Financial Officer was terminated effective July 20, 2018. Pursuant to the provisions of the 2016 Omnibus Incentive Plan and terms and conditions of his stock option Award Agreement, the non-exercisable portion of his option grant or 14,649 expired upon his termination and the exercisable portion or 131,851 options remained exercisable for 90 days following his termination. The prior Chief Financial Officer failed to exercise his exercisable options within the 90 day period and they were forfeited as of October 18, 2018. Susan Montoya, our Senior Vice President of Operations and Quality Assurance/Regulatory Affairs resigned as of November 15, 2018 from the Company. Pursuant to the provisions of the 2016 Omnibus Incentive Plan and terms and conditions of her stock option Award Agreement, the exercisable portion or 818,500 options remained exercisable for 90 days following her resignation date. Ms. Montoya failed to exercise her exercisable options within the 90 day period and they were forfeited as of February 13, 2019. Restricted Stock Units Under the Company’s Restricted Stock Units Outstanding Restricted Stock Units Exercisable Grant Date Closing Stock Price Exercisable Into Outstanding Number of Units Weighted Average Remaining Life In Years Exercisable Number of Units $ 1.97 Common Stock 87,549 9.9 -

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 16 – Related Party Transactions Contract & Research Revenue – Related Party During the years ended December 31, 2018 and 2017, the Company recognized $70,400 and $99,600, respectively of revenue for contract research services provided pursuant to a Development and Manufacturing Agreement with HJLA dated April 1, 2016. Advances to Related Party During the year ended December 31, 2017, the Company paid $206,000 as short-term advances to HJLA, and received repayments from HJLA of $216,000. The balance of advances outstanding as of December 31, 2017 was $0. Loan Receivable - Related Party On June 15, 2017, the Company entered into a promissory note agreement (the “Note Receivable”) with HJLA, pursuant to which the Company loaned $160,000 to HJLA. The Note Receivable bears interest at 15% per annum, and all unpaid principal and interest was due on September 15, 2017. During the year ended December 31, 2017, the note principal, along with $6,685 of accrued interest was repaid in full.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events On January 2, 2019, H. Chris Sarner began her employment with the Company as our Vice President Regulatory Affairs and Quality Assurances and entered into an employment agreement with the Company which provides for an annual base salary of $225,000 as well as standard employee insurance and other benefits. Pursuant to this agreement, Ms. Sarner is eligible for annual salary increases at the sole discretion of our Chief Executive Officer. Per her employment agreement, Ms. Sarner was granted stock options for the right to purchase 150,000 shares at an exercise price of $1.59, equal to the closing price of our common stock on February 7, 2019, the date that the Board approved the option grant. The options vest quarterly, over a 3 year period, with a 1 year cliff. The stock options were granted in accordance with our Amended and Restated 2016 Omnibus Incentive Plan. Ms. Sarner’s employment with the Company is “at-will”, and may be terminated at any time, with or without cause and with or without notice by either Ms. Sarner or the Company. On January 3, 2019, the Company entered into an Agreement (“Alere Agreement”) with Alere Financial Partners, a division of Cova Capital Partners LLC (“Alere”) for Alere to provide capital markets advisory services. The Alere Agreement is on a month to month basis that can be cancelled by either party with thirty (30) days advance notice. The Company will pay a monthly fee of $7,500 and will issue 35,000 warrants to Alere with a strike price of $1.59, equal to the closing price of the Company’s common stock on February 7, 2019, the date of approval by the Company’s board of directors. The warrants shall vest equally monthly over a 12 month period provided that the Alere Agreement remains in effect. On January 7, 2019, Dr. Peter Pappas agreed to join the Company’s Medical Advisory Board for a term of two years. As compensation, Dr Pappas will receive twenty thousand (20,000) options to purchase shares of the Company’s common stock at a price equal to the closing share price for the Company’s common stock on the day that the Company’s board of directors approves the grant. The options will vest monthly in twenty-four (24) equal installments for each month that he remains a member of the Company’s Medical Advisory Board. On January 18, 2019, the Superior Court granted to ATSCO, Inc., who had filed a complaint with the Superior Court on September 25, 2018 (see Note 11 to the Financial Statements – Commitments and Contingencies under Litigations Claims and Assessments On February 7, 2019, the Company entered into an Agreement (“MZ Agreement”) with MZHCI, LLC a MZ Group Company (“MZ” for MZ to provide investor relations advisory services. The MZ Agreement is for a term of twelve (12) months, that can be cancelled by either party at the end of six (6) months with thirty (30) day notice. After the full twelve (12) month term, the MZ Agreement will automatically renew every (6) months thereafter unless either party to the other delivers written notice of termination at least thirty (30) days notice prior to the end of the then current MZ Agreement. MZ will receive compensation of $8,000 per month and eight-five thousand (85,000) restricted shares that vest quarterly over a year, with a 6 month cliff, that either party can terminate the agreement after 6 months but if the agreement is terminated by MZ at the end of six months, MZ forfeits the restricted shares. On February 7, 2019, the Company’s board of directors approved the grant of 30,000 stock options to H. Jorge Ulloa as compensation for services provided as the Company’s Primary Investigator for the first-in-human trials of our VenoValve in Colombia in the first quarter 2019. The stock options were granted at an exercise price of $1.59, equal to the closing price of our common stock on February 7, 2019, the date that the Board approved the option grant. The options vest monthly, over a one (1) year period. On March 12, 2019, the Company raised $2,714,000 in gross proceeds a private placement offering of its common stock to certain accredited investors (the “Offering”). The Company sold an aggregate of 2,360,051 shares of common stock in the Offering for a purchase price of $1.15 per share pursuant to a share purchase agreement between the Company and each of the investors in the offering (the “Purchase Agreement”). Pursuant to the terms of the Purchase Agreement, the Company has agreed to file a registration statement with the Securities and Exchange Commission for the resale of the purchasers’ shares on or before March 31, 2019 and to use commercially reasonable efforts to have the registration statement declared effective within ninety days of the filing date. The Purchase Agreement also contains customary representations, warranties and agreements. The Company engaged Network 1 Financial Securities, Inc., a FINRA-member (the “Placement Agent”), to act as exclusive placement agent for the Offering. The Placement Agent is entitled to a warrant to purchase 188,804 shares of the Company’s common stock. Such warrant will be exercisable for a period of five years from the date of issuance and will have an exercise price of $1.50. The Company received $2,326,176 in net proceeds after giving effect to estimated offering fees and expenses of $387,824. For illustration purposes, attached as Exhibit 99.1 of this report are the unaudited cash and stockholders’ equity balances that the Company believes are as of March 12, 2019.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance related to the Company’s deferred tax assets, and the valuation of warrants and derivative liabilities.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs, which primarily consist of direct, incremental professional fees relating to the IPO, have been capitalized within non-current assets and were offset against the IPO proceeds upon the consummation of the IPO. Deferred offering costs of $2,542,555, consisting primarily of legal, accounting and underwriting fees of which $880,679 of the deferred offering costs were incurred in 2017, and the full amount was charged to additional paid in capital upon the consummation of the IPO on June 4, 2018.
Investments	Investments Equity investments over which the Company exercises significant influence, but does not control, are accounted for using the equity method, whereby investment accounts are increased (decreased) for the Company’s proportionate share of income (losses), but investment accounts are not reduced below zero. The Company holds a 28.5% ownership investment, consisting of founders’ shares acquired at nominal cost, in HJLA. To date, HJLA has recorded cumulative losses. Since the Company’s investment is recorded at $0, the Company has not recorded its proportionate share of HJLA’s losses. If HJLA reports net income in future years, the Company will apply the equity method only after its share of HJLA’s net income equals its share of net losses previously incurred.
Property and Equipment, Net	Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, which range from 5 to 7 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. FASB ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Quoted prices available in active markets for identical assets or liabilities trading in active markets. Level 2 Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. Financial instruments, including accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company’s other financial instruments include notes payable, the carrying value of which approximates fair value, as the notes bear terms and conditions comparable to market for obligations with similar terms and maturities. Derivative liabilities are accounted for at fair value on a recurring basis. The fair value of derivative liabilities as of December 31, 2018 and December 31, 2017, by level within the fair value hierarchy appears below: Description: Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liabilities - Preferred Stock Series A Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 541,990 Derivative liabilities - Preferred Stock Series B Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 60,551 Derivative liabilities - Convertible Debt Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 1,298,012 Derivative liabilities - Convertible Debt Embedded Conversion Feature December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 1,176,365 The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Derivative Liabilities Balance – January 1, 2017 $ 551,351 Issuance of derivative liabilities - common stock Series B warrants 57,283 Issuance of derivative liabilities - convertible debt warrants 1,268,177 Issuance of derivative liabilities - convertible debt conversion feature 2,349,560 Extinguishment of derivative liabilities - convertible debt conversion feature (1,175,668 ) Change in fair value of derivative liabilities 26,215 Balance - December 31, 2017 3,076,918 Issuance of derivative liabilities - convertible debt warrants 1,942,362 Issuance of derivative liabilities - convertible debt embedded conversion feature 3,652,588 Extinguishment of derivative liabilities upon debt modification (2,420,390 ) Change in fair value of derivative liabilities (191,656 ) Extinguishment of derivative liabilities upon conversion of debt (2,465,820 ) Reclassification of warrant derivatives to equity (3,594,002 ) Balance - December 31, 2018 $ -
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity under U.S. GAAP when determining the classification and measurement of its Series A and Series B Preferred Stock (together, the “Preferred Stock”). Preferred stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable preferred stock (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, preferred stock is classified as permanent equity. As of the issuance date, the carrying amount of the Preferred Stock was less than the redemption value. If the Company were to determine that redemption was probable, the carrying value would be increased by periodic accretions such that the carrying value would equal the redemption amount at the earliest redemption date. Such accretion would be recorded as a preferred stock dividend (see Note 12 to the Financial Statements – Temporary Equity).
Derivative Liabilities	Derivative Liabilities Derivative financial instruments are recorded as a liability at fair value and are marked-to-market as of each balance sheet date. The change in fair value at each balance sheet date is recorded as a change in the fair value of derivative liabilities on the statement of operations for each reporting period. The fair value of the derivative liabilities was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The Company reassesses the classification of the financial instruments at each balance sheet date. If the classification changes as a result of events during the period, the financial instrument is marked to market and reclassified as of the date of the event that caused the reclassification. On June 4, 2018, in connection with the Company’s IPO, all of its previously issued convertible notes were converted and paid in full (as discussed in Note 8 to the Financial Statements - Convertible Notes and Convertible Note – Related Party), and the embedded conversion options and warrants no longer qualified as derivatives; accordingly, the derivative liabilities were remeasured to fair value on June 4, 2018 and the fair value of derivative liabilities of $3,594,002 was reclassified to additional paid in capital (see Fair Value of Financial Instruments, above). The Company recorded a gain and a loss on the change in fair value of derivative liabilities of $191,656 and $26,215 during the years ended December 31, 2018 and 2017, respectively.
Convertible Notes	Convertible Notes The convertible notes payable discussed in Note 8 to the Financial Statements – Convertible Notes and Convertible Note – Related Party, had a conversion price that could be adjusted based on the Company’s stock price, which resulted in the conversion feature being recorded as a derivative liability and a debt discount. The debt discount was amortized to interest expense over the life of the respective note, using the effective interest method. On June 4, 2018, principal of $10,000 owed on the Convertible Notes was paid in cash, and all of the remaining principal and interest owed pursuant to the Convertible Notes were converted into common stock in connection with the Company’s IPO. The conversion of the Convertible Notes was deemed to be a debt extinguishment; accordingly, the warrant and embedded conversion option derivative liabilities were remeasured to fair value on June 4, 2018 and reclassified to additional paid in capital (See Derivative Liabilities, above).
Net Loss Per Share	Net Loss per Share The Company computes basic and diluted loss per share by dividing net loss attributable to common stockholders by the weighted average number of common stock outstanding during the period. Net loss income attributable to common stockholders consists of net loss, adjusted for the convertible preferred stock deemed dividend resulting from the 8% cumulative dividend on the Preferred Stock and the beneficial conversion feature recorded in connection with the conversion of the Preferred Stock (see Note 12 to the Financial Statements – Temporary Equity). Basic and diluted net loss per common share are the same since the inclusion of common stock issuable pursuant to the exercise of warrants and options, plus the conversion of preferred stock or convertible notes, in the calculation of diluted net loss per common shares would have been anti-dilutive. The following table summarizes net loss attributable to common stockholders used in the calculation of basic and diluted loss per common share: For the Years Ended December 31, 2018 2017 Net loss $ (13,042,709 ) $ (7,791,469 ) Deemed dividend to Series A and B preferred stockholders (3,310,001 ) (459,917 ) Net loss attributable to common stockholders $ (16,352,710 ) $ (8,251,386 ) The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of December 31, 2018 and 2017: December 31, 2018 2017 Shares of common stock issuable upon conversion of preferred stock - 629,746 Shares of common stock issuable upon exercise of preferred stock warrants and the subsequent conversion of the preferred stock issued therewith - 50,285 Shares of common stock issuable upon the conversion of convertible debt - 229,208 Shares of common stock issuable upon exercise of warrants 3,780,571 371,216 Shares of common stock issuable upon exercise of options and restricted stock units 2,883,256 1,422,000 Potentially dilutive common stock equivalents excluded from diluted net loss per share 6,663,827 2,702,455
Revenue Recognition	Revenue Recognition In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers - Principal versus Agent Considerations”, in April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing” and in May 9, 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606)”, or ASU 2016-12. This update provides clarifying guidance regarding the application of ASU No. 2014-09 - Revenue From Contracts with Customers which is not yet effective. These new standards provide for a single, principles-based model for revenue recognition that replaces the existing revenue recognition guidance. In July 2015, the FASB deferred the effective date of ASU 2014-09 until annual and interim periods beginning on or after December 15, 2017. It has replaced most existing revenue recognition guidance under U.S. GAAP. The ASU may be applied retrospectively to historical periods presented or as a cumulative-effect adjustment as of the date of adoption. The Company adopted Topic 606 using a modified retrospective approach and will be applied prospectively in the Company’s financial statements from January 1, 2018 forward. Revenues under Topic 606 are required to be recognized either at a “point in time” or “over time”, depending on the facts and circumstances of the arrangement, and will be evaluated using a five-step model. The adoption of Topic 606 did not have a material impact on the Company’s financial statements, at initial implementation nor will it have a material impact on an ongoing basis. The Company recognizes revenue when goods or services are transferred to customers in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. In determining when and how revenue is recognized from contracts with customers, the Company performs the following five-step analysis: (i) identification of contract with customer; (ii) determination of performance obligations; (iii) measurement of the transaction price; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The following table summarizes the Company’s revenue recognized in the accompanying statements of operations: For the Years Ended December 31, 2018 2017 Product sales $ - $ 184,800 Royalty income 116,152 137,711 Contract research - related party 70,400 99,600 Total Revenues $ 186,552 $ 422,111 Revenue from sales of products is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the product is shipped to the customer. Royalty revenue, which is based on resales of ProCol Vascular Bioprosthesis to third-parties, will be recorded when the third-party sale occurs and the performance obligation has been satisfied. Contract research and development revenue is recognized over time using an input model, based on labor hours incurred to perform the research services, since labor hours incurred over time is thought to best reflect the transfer of service. Information on Remaining Performance Obligations and Revenue Recognized from Past Performance Information about remaining performance obligations pertaining to contracts that have an original expected duration of one year or less is not disclosed. The transaction price allocated to remaining unsatisfied or partially unsatisfied performance obligations with an original expected duration exceeding one year was not material at September 30, 2018. Contract Balances The timing of our revenue recognition may differ from the timing of payment by our customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, deferred revenue is recorded until the performance obligations are satisfied. The Company had deferred revenue of $33,000 and $103,400 as of December 31, 2018 and 2017, respectively, related to cash received in advance for contract research and development services. The Company expects to satisfy its remaining performance obligations for contract research and development services and recognize the deferred revenue over the next twelve months.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and recognized over the period services are required to be provided in exchange for the award, usually the vesting period. Forfeitures of unvested stock options are recorded when they occur.
Concentrations	Concentrations The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. There were aggregate uninsured cash balances of $2,490,645 at December 31, 2018. There were no cash balances in excess of federally insured amounts at December 31, 2017. During the year ended December 31, 2017, 44% of the Company’s revenues were from the sub-contract manufacture of product for LeMaitre Vascular, Inc. (“LeMaitre”), and 33% were from royalties earned from the sale of product by LeMaitre, with whom the Company entered a three-year Post-Acquisition Supply Agreement effective March 18, 2016. During the year ended December 31, 2018, 62% of the Company’s revenues were from royalties earned from the sale of product by LeMaitre. The three-year Post-Acquisition Supply Agreement from which the Company earns royalty from the sale of product by LeMaitre ends on March 18, 2019. The Company did not recognize any subcontract manufacturing revenues during the year ended December 31, 2018. During the years ended December 31, 2018 and 2017, 38% and 24%, respectively, of the Company’s revenues were earned from contract research and development services performed for HJLA.
Subsequent Events	Subsequent Events The Company evaluated events that have occurred after the balance sheet date through the date the financial statements were issued. Based upon the evaluation and transactions, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed in Note 17 to the Financial Statements - Subsequent Events.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018. As a result of the new standard, all of our leases greater than one year in duration will be recognized in our Balance Sheets as both operating lease liabilities and right-of-use assets upon adoption of the standard. We will adopt the standard using the prospective approach. Upon adoption, we expect to record approximately $1.1 million in right-of-use assets and operating lease liabilities in our Balance Sheets. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments (Topic 230)” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. ASU 2016-15 requires adoption on a retrospective basis unless it is impracticable to apply, in which case the Company would be required to apply the amendments prospectively as of the earliest date practicable. The adoption of ASU 2016-15 did not have a material impact on the Company’s financial statements. In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718); Scope of Modification Accounting. The amendments in this ASU provide guidance that clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. If the fair value, vesting conditions or classification of the award changes, modification accounting will apply. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2017-09 did not have a material impact on the Company’s financial statements. On June 20, 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting, which simplifies accounting for share-based payment transactions resulting for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard was adopted effective April 1, 2018, using the modified retrospective approach; however, the Company did not identify or record any adjustments to the opening balance of retained earnings on adoption. The new standard did not have a material impact on the Company’s financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Fair Value of Derivative Liabilities	The fair value of derivative liabilities as of December 31, 2018 and December 31, 2017, by level within the fair value hierarchy appears below: Description: Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liabilities - Preferred Stock Series A Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 541,990 Derivative liabilities - Preferred Stock Series B Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 60,551 Derivative liabilities - Convertible Debt Warrants December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 1,298,012 Derivative liabilities - Convertible Debt Embedded Conversion Feature December 31, 2018 $ - $ - $ - December 31, 2017 $ - $ - $ 1,176,365
Schedule of Derivative Liabilities at Fair Value on Recurring Basis	The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Derivative Liabilities Balance – January 1, 2017 $ 551,351 Issuance of derivative liabilities - common stock Series B warrants 57,283 Issuance of derivative liabilities - convertible debt warrants 1,268,177 Issuance of derivative liabilities - convertible debt conversion feature 2,349,560 Extinguishment of derivative liabilities - convertible debt conversion feature (1,175,668 ) Change in fair value of derivative liabilities 26,215 Balance - December 31, 2017 3,076,918 Issuance of derivative liabilities - convertible debt warrants 1,942,362 Issuance of derivative liabilities - convertible debt embedded conversion feature 3,652,588 Extinguishment of derivative liabilities upon debt modification (2,420,390 ) Change in fair value of derivative liabilities (191,656 ) Extinguishment of derivative liabilities upon conversion of debt (2,465,820 ) Reclassification of warrant derivatives to equity (3,594,002 ) Balance - December 31, 2018 $ -
Schedule of Basic and Diluted Loss Per Common Share	The following table summarizes net loss attributable to common stockholders used in the calculation of basic and diluted loss per common share: For the Years Ended December 31, 2018 2017 Net loss $ (13,042,709 ) $ (7,791,469 ) Deemed dividend to Series A and B preferred stockholders (3,310,001 ) (459,917 ) Net loss attributable to common stockholders $ (16,352,710 ) $ (8,251,386 )
Summary of Potentially Dilutive of Common Share	The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of December 31, 2018 and 2017: December 31, 2018 2017 Shares of common stock issuable upon conversion of preferred stock - 629,746 Shares of common stock issuable upon exercise of preferred stock warrants and the subsequent conversion of the preferred stock issued therewith - 50,285 Shares of common stock issuable upon the conversion of convertible debt - 229,208 Shares of common stock issuable upon exercise of warrants 3,780,571 371,216 Shares of common stock issuable upon exercise of options and restricted stock units 2,883,256 1,422,000 Potentially dilutive common stock equivalents excluded from diluted net loss per share 6,663,827 2,702,455
Schedule of Revenue Recognized	The following table summarizes the Company’s revenue recognized in the accompanying statements of operations: For the Years Ended December 31, 2018 2017 Product sales $ - $ 184,800 Royalty income 116,152 137,711 Contract research - related party 70,400 99,600 Total Revenues $ 186,552 $ 422,111

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	As of December 31, 2018 and 2017, property and equipment consist of the following: December 31, 2018 2017 Lab equipment $ 94,905 $ 120,861 Furniture and fixtures 93,417 93,417 Computer software and equipment 26,830 14,409 Leasehold improvements 158,092 158,092 373,244 386,779 Less: accumulated depreciation (347,091 ) (362,936 ) Property and equipment, net $ 26,153 $ 23,843

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	As of December 31, 2018 and 2017, the Company’s intangible assets consisted of the following: December 31, 2018 2017 Patent $ 1,100,000 $ 1,100,000 Right to develop and manufacture - 445,200 1,100,000 1,545,200 Less: accumulated amortization (433,533 ) (435,790 ) Total $ 666,467 $ 1,109,410
Schedule of Estimated Future Amortization of Intangible Assets	The estimated future amortization of Patent is as follows: For the Years Ended December 31, Patent 2019 $ 77,647 2020 77,647 2021 77,647 2022 77,647 2023 77,647 Thereafter 278,232 $ 666,467

Accrued Expenses and Accrued _2

Accrued Expenses and Accrued Interest - Related Party (Tables)	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	As of December 31, 2018 and 2017, accrued expenses consist of the following: December 31, 2018 2017 Accrued compensation costs $ 288,549 $ 556,118 Accrued professional fees 55,300 235,654 Deferred rent 22,473 4,978 Accrued interest - 101,050 Accrued franchise taxes 26,985 - Accrued research and development 17,064 - Other accrued expenses 2,500 5,794 Accrued expenses $ 412,871 $ 903,594

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Income Tax Provision (Benefit)	The following summarizes the Company’s income tax provision (benefit): For the Years Ended December 31, 2018 2017 Federal: Current $ - $ - Deferred (1,710,997 ) (138,931 ) State and local: Current - - Deferred (570,332 ) (479,833 ) (2,281,329 ) (618,764 ) Change in valuation allowance 2,281,329 618,764 Income tax provision (benefit) $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	For the Years Ended December 31, 2018 2017 Tax benefit at federal statutory rate (21.0 )% (34.0 )% State taxes, net of federal benefit (7.0 )% (6.0 )% Permanent differences 11.4 % 9.4 % True up adjustments (0.9 )% 1.3 % Effect of change in tax rate 0.0 % 21.3 % Change in valuation allowance 17.5 % 7.9 % Effective income tax rate (0.0 )% (0.0 )%
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets at December 31, 2018 and 2017 are as follows: December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 5,298,599 $ 3,122,308 Research and development credit carryforwards 185,680 185,680 Intangible assets 152,109 48,629 Property and equipment 30,957 34,974 Accrued salaries - 106,400 Stock-based compensation 526,945 419,868 Deferred rent 6,292 1,394 Impairment loss 136,612 136,612 Total gross deferred tax assets 6,337,194 4,055,865 Less: valuation allowance (6,337,194 ) (4,055,865 ) Total $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments for Operating Leases	Future minimum lease payments under the Company’s operating leases are as follows: For The Years Ending December 31, Amount 2019 $ 334,203 2020 344,229 2021 354,561 2022 271,854 Total 1,304,847

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Schedule of Stock Warrant Activity	A summary of warrant activity during the years ended December 31, 2018 and 2017 is presented below: Series A Preferred Stock Common Stock Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life in Years Intrinsic Value Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life in Years Intrinsic Value Outstanding, January 1, 2017 100,570 $ 5.00 416,666 12.00 Issued [1] 204,550 12.00 Exercised Cancelled (250,000 ) Outstanding, January 1, 2018 100,570 $ 5.00 371,216 $ 12.00 Issued - - 3,292,443 6.09 Exercised - - - - Cancelled - - - - Amendment of placement agent warrants [2] (100,570 ) 5.00 116,912 4.30 Outstanding, December 31, 2018 - $ - - $ - 3,780,571 $ 5.48 [3] 4.1 $ - Exercisable, December 31, 2018 - $ - - $ - 3,780,571 $ 5.48 4.1 $ - [1] Warrants granted in 2017 consist of Series B warrants for purchase of 17,303 shares, convertible note debt holder warrants for purchase of 171,908 shares and convertible note placement agent warrants for purchase of 15,339 shares of common stock. [2] In connection with the IPO, placement agent warrants for the purchase of Series A Preferred Stock were amended such that the warrants became exercisable for the number of common stock that would have been issued upon the exercise of the Series A warrant and subsequent conversion to common stock upon the consummation of the IPO. The exercise price was amended to the price equal to the total proceeds that would have been required upon the exercise of the original warrant, divided by the amended number of warrant shares. The amendment was accounted for as a modification of a stock award. The Company determined that there was no incremental increase in the fair value for the amendment of the award and accordingly there was no charge to the statement of operations for the years ended December 31, 2018. [3] Pursuant to the terms of the warrant, the exercise price of the warrants issued to investors and the placement agent in connection with the sale of the Convertible Notes became fixed at $4.20 per share and $4.62 per share, respectively, at the date of the IPO, based upon the price of stock issued in the IPO.
Schedule of Outstanding and Exercisable Warrants	A summary of outstanding and exercisable warrants as of December 31, 2018 is presented below: Warrants Outstanding Warrants Exercisable Exercise Price Exercisable Into Outstanding Number of Warrants Weighted Average Remaining Life in Years Exercisable Number of Warrants $ 12.00 Common Stock 183,969 4.5 183,969 $ 6.25 Common Stock 75,000 4.4 75,000 $ 6.00 Common Stock 1,725,000 4.4 1,725,000 $ 4.99 Common Stock 100,000 4.5 100,000 $ 4.62 Common Stock 138,392 3.9 138,392 $ 4.30 Common Stock 116,912 2.1 116,912 $ 4.20 Common Stock 1,441,298 3.8 1,441,298 3,780,571 3,780,571

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Option Activity	A summary of the option activity during the years ended December 31, 2018 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2018 1,422,000 $ 10.16 Granted 1,520,207 4.46 Forfeited (146,500 ) 10.00 Outstanding, December 31, 2018 2,795,707 $ 7.07 9.0 $ - Exercisable, December 31, 2018 1,865,604 $ 8.50 8.4 $ -
Schedule of Outstanding and Exercisable Options	A summary of outstanding and exercisable options and Restricted Stock units as of December 31, 2018 is presented below: Options Outstanding Options Exercisable Exercise Price Exercisable Into Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $ 12.00 Common Stock 120,000 8.7 120,000 $ 10.00 Common Stock 1,149,500 7.8 1,149,500 $ 7.00 Common Stock 6,000 8.9 6,000 $ 4.99 Common Stock 1,080,207 9.7 540,104 $ 4.93 Common Stock 80,000 9.5 20,000 $ 2.98 Common Stock 150,000 9.5 - $ 2.90 Common Stock 30,000 9.9 30,000 $ 2.57 Common Stock 180,000 9.9 - Total 2,795,707 1,865,604
Schedule of Outstanding and Exercisable Restricted Stock Units	Restricted Stock Units Outstanding Restricted Stock Units Exercisable Grant Date Closing Stock Price Exercisable Into Outstanding Number of Units Weighted Average Remaining Life In Years Exercisable Number of Units $ 1.97 Common Stock 87,549 9.9 -

Initial Public Offering (Detail

Initial Public Offering (Details Narrative) - USD ($)	Dec. 02, 2018	Nov. 27, 2018	Jun. 12, 2018	Jun. 08, 2018	Jun. 04, 2018	May 30, 2018	Dec. 31, 2018		Dec. 31, 2017
Number shares issued for initial public offering, shares	2,005	3,334			1,500,000
Sale of stock price per share					$ 5
Sale of stock description						Consisting of one share of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and a warrant to purchase one share of common stock with an exercise price of $6.00 per share
Common stock, par value						$ 0.00001	$ 0.00001		$ 0.00001
Stock of warrant exercise price						$ 6
Gross proceeds from initial public offering						$ 7,500,000	$ 7,657,427	[1]		[1]
Additional Units [Member]
Number shares issued for initial public offering, shares				225,000
Sale of stock description				On June 8, 2018, the underwriters notified the Company of their exercise in full of their option to purchase an additional 225,000 Units (the "Additional Units") to cover over-allotments.
Additional Units [Member] | Initial Public Offering [Member]
Sale of stock price per share			$ 5
Gross proceeds from initial public offering			$ 1,125,000
[1]	Net of offering costs paid from escrow of $967,573

Going Concern and Management'_2

Going Concern and Management's Liquidity Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 13,042,709	$ 7,791,469
Accumulated deficit	48,562,528	35,519,819
Net cash used in operating activities	6,355,838	$ 4,202,240
Cash balance	2,740,645
Working capital	$ 1,313,980

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	Jun. 04, 2018	Dec. 31, 2018	Dec. 31, 2017
Deferred offering costs			$ 880,679
Investments		0
Change in fair value of derivative liabilities		$ (191,656)	26,215
Convertible notes payable, principal amount	$ 10,000
Cumulative dividend percentage		8.00%
Deferred revenue		$ 33,000	$ 103,400
FDIC insured amount		250,000
Uninsured cash balance		2,490,645
Right of usee assets and operating lease liabilities		$ 1,100,000
LeMaitre Vascular, Inc [Member] | Revenue [Member]
Concentration risk percentage		62.00%	44.00%
LeMaitre Vascular, Inc [Member] | Revenue [Member] | Three-Year Post-Acquisition Supply Agreement [Member]
Concentration risk percentage			33.00%
Hancock Jaffe Laboratory Aesthetics, Inc [Member] | Revenue [Member]
Concentration risk percentage		38.00%	24.00%
Minimum [Member]
Estimated useful life of property and equipment		5 years
Maximum [Member]
Estimated useful life of property and equipment		7 years
Hancock Jaffe Laboratory Aesthetics, Inc [Member]
Ownership percentage		28.50%
Initial Public Offering [Member]
Deferred offering costs	2,542,555	$ 2,542,555
Fair value of derivative liabilities reclassified to additional paid in capital	$ 3,594,002

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Fair Value of Derivative Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Derivative liabilities		$ 3,076,918
Preferred Stock Series A Warrants [Member] | Level 1 [Member]
Derivative liabilities
Preferred Stock Series A Warrants [Member] | Level 2 [Member]
Derivative liabilities
Preferred Stock Series A Warrants [Member] | Level 3 [Member]
Derivative liabilities		541,990
Preferred Stock Series B Warrants [Member] | Level 1 [Member]
Derivative liabilities
Preferred Stock Series B Warrants [Member] | Level 2 [Member]
Derivative liabilities
Preferred Stock Series B Warrants [Member] | Level 3 [Member]
Derivative liabilities		60,551
Convertible Debt Warrants [Member] | Level 1 [Member]
Derivative liabilities
Convertible Debt Warrants [Member] | Level 2 [Member]
Derivative liabilities
Convertible Debt Warrants [Member] | Level 3 [Member]
Derivative liabilities		1,298,012
Convertible Debt Embedded Conversion Feature [Member] | Level 1 [Member]
Derivative liabilities
Convertible Debt Embedded Conversion Feature [Member] | Level 2 [Member]
Derivative liabilities
Convertible Debt Embedded Conversion Feature [Member] | Level 3 [Member]
Derivative liabilities		$ 1,176,365

Significant Accounting Polici_6

Significant Accounting Policies - Schedule of Derivative Liabilities at Fair Value on Recurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Derivative liabilities, beginning balance	$ 3,076,918	$ 551,351
Issuance of derivative liabilities - common stock Series B warrants		57,283
Issuance of derivative liabilities - convertible debt warrants	1,942,362	1,268,177
Issuance of derivative liabilities - convertible debt conversion feature		2,349,560
Extinguishment of derivative liabilities - convertible debt conversion feature		(1,175,668)
Change in fair value of derivative liabilities	(191,656)	26,215
Issuance of derivative liabilities - convertible debt embedded conversion feature	3,652,588
Extinguishment of derivative liabilities upon debt modification	(2,420,390)
Extinguishment of derivative liabilities upon conversion of debt	(2,465,820)
Reclassification of warrant derivatives to equity	(3,594,002)
Derivative liabilities, ending balance		$ 3,076,918

Significant Accounting Polici_7

Significant Accounting Policies - Schedule of Basic and Diluted Loss Per Common Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Net loss	$ (13,042,709)	$ (7,791,469)
Deemed dividend to Series A and B preferred stockholders	(3,310,001)	(459,917)
Net loss attributable to common stockholders	$ (16,352,710)	$ (8,251,386)

Significant Accounting Polici_8

Significant Accounting Policies - Summary of Potentially Dilutive of Common Share (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Potentially dilutive common stock equivalents excluded from diluted net loss per share	6,663,827	2,702,455
Convertible Preferred Stock [Member]
Potentially dilutive common stock equivalents excluded from diluted net loss per share		629,746
Preferred Stock Warrants [Member]
Potentially dilutive common stock equivalents excluded from diluted net loss per share		50,285
Convertible Debt [Member]
Potentially dilutive common stock equivalents excluded from diluted net loss per share		229,208
Warrants [Member]
Potentially dilutive common stock equivalents excluded from diluted net loss per share	3,780,571	371,216
Options and Restricted Stock Units [Member]
Potentially dilutive common stock equivalents excluded from diluted net loss per share	2,883,256	1,422,000

Significant Accounting Polici_9

Significant Accounting Policies - Schedule of Revenue Recognized (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total Revenues	$ 186,552	$ 422,111
Product Sales [Member]
Total Revenues		184,800
Royalty Income [Member]
Total Revenues	116,152	137,711
Contract Research - Related Party [Member]
Total Revenues	$ 70,400	$ 99,600

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation and amortization expense	$ 10,112	$ 15,905
Lab Equipment [Member]
Write off of equipment	$ 25,956

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property and equipment	$ 373,244	$ 386,779
Less: accumulated depreciation	(347,091)	(362,936)
Property and equipment, net	26,153	23,843
Lab Equipment [Member]
Property and equipment	94,905	120,861
Furniture and Fixtures [Member]
Property and equipment	93,417	93,417
Computer Software and Equipment [Member]
Property and equipment	26,830	14,409
Leasehold Improvements [Member]
Property and equipment	$ 158,092	$ 158,092

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	Apr. 01, 2016	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset expiration	Dec. 31, 2025	Jul. 9, 2027
Payments to acquire intangible assets	$ 445,200
Impairment loss		$ 319,635
Amortization expense		$ 123,308	$ 123,308
Amortization period of asset		8 years 6 months

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Intangible assets	$ 1,100,000	$ 1,545,200
Less: accumulated amortization	(433,533)	(435,790)
Total	666,467	1,109,410
Patents [Member]
Intangible assets	1,100,000	1,100,000
Right to Develop and Manufacture [Member]
Intangible assets		$ 445,200

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Estimated Future Amortization of Intangible Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 77,647
2020	77,647
2021	77,647
2022	77,647
2023	77,647
Thereafter	278,232
Total	$ 666,467	$ 1,109,410

Accrued Expenses and Accrued _3

Accrued Expenses and Accrued Interest - Related Party (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accrued interest - related parties		$ 20,558
Chief Financial Officer [Member]
Accrued severance expense	$ 166,154

Accrued Expenses and Accrued _4

Accrued Expenses and Accrued Interest - Related Party - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued compensation costs	$ 288,549	$ 556,118
Accrued professional fees	55,300	235,654
Deferred rent	22,473	4,978
Accrued interest		101,050
Accrued franchise taxes	26,985
Accrued research and development	17,064
Other accrued expenses	2,500	5,794
Accrued expenses	$ 412,871	$ 903,594

Convertible Notes and Convert_2

Convertible Notes and Convertible Note - Related Party (Detail Narrative) - USD ($)		Jun. 04, 2018	Apr. 26, 2018	Feb. 28, 2018	Jan. 16, 2018	Dec. 07, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 02, 2018	Nov. 27, 2018	May 30, 2018	Apr. 01, 2016	Jun. 30, 2015
Proceeds from convertible promissory notes	[1]						$ 2,603,750	$ 2,564,400
Debt maturity date								Sep. 15, 2017
Debt interest rate								15.00%
Warrant exercise price per share											$ 6
Gain on extinguishment of debt							1,481,317	$ 257,629
Debt instrument, principal amount		$ 10,000
Accrued interest								101,050
Interest expense							$ 305,452	172,800
Common stock percentage							50.00%		25.00%	25.00%
2017 Convertible Notes [Member]
Convertible promissory notes						$ 2,750,500
Debt offering cost						186,100
Placement agent fees						129,030
Proceeds from convertible promissory notes						$ 2,564,400
Debt maturity date				May 15, 2018		Feb. 28, 2018
Debt interest rate						15.00%
Debt conversion description						The 2017 Convertible Notes included warrants exercisable for the number of shares of common stock equal to 75% of the total shares issuable upon the conversion of the related 2017 Convertible Note, at a price equal to the lesser of (i) $14.40 per share or (ii) 120% of the 2017 Conversion Price.
Warrant term						5 years
Warrants to purchase shares						15,339
Warrant exercise price per share						$ 15.84
Fair value of options issued						$ 1,175,668
Fair value of warrants issued						397,211
Debt discount						$ 1,572,879
Warrant exercise price percentage				100.00%
2018 Convertible Notes [Member]
Convertible promissory notes					$ 2,897,500
Debt offering cost					293,750
Placement agent fees					289,750
Proceeds from convertible promissory notes					$ 2,603,750
Debt maturity date					Feb. 28, 2018
Debt interest rate					15.00%
Debt conversion description					The 2018 Convertible Notes include five-year warrants exercisable for the number of common stock equal to 50% of the total shares issuable upon the conversion of the 2018 Convertible Note, at a price equal to the lesser of (i) $14.40 per share or (ii) 120% of the 2018 Conversion price.
Warrant term					5 years
Warrants to purchase shares					24,146
Fair value of options issued					$ 1,239,510
Fair value of warrants issued					1,046,763
Debt discount					$ 2,286,273
Warrant exercise price percentage				75.00%	110.00%
Convertible Notes [Member]
Debt discount							$ 2,413,079
Gain on extinguishment of debt		5,743,391					1,524,791
Gain on extinguishment of derivatives							2,420,390
Proceeds from issuance of warrants							895,599
Debt instrument, principal amount		10,000
Accrued interest		$ 267
Debt converted into shares		1,650,537
Debt conversion price per share		$ 3.50
Loss on convertible notes payable		$ 43,474
Debt conversion amount		8,252,685
Derivative liabilities		$ 2,465,820
2015 Note [Member]
Proceeds from convertible promissory notes							0	311,000
Debt interest rate													3.00%
Debt converted into shares			120,405
Debt conversion price per share			$ 4.30									$ 10
Interest expense							$ 4,613	$ 13,886
Common stock percentage													78.00%
Maximum borrowing capacity													$ 2,200,000
[1]	Net of cash offering costs of $186,100

Notes Payable and Note Payabl_2

Notes Payable and Note Payable - Related Party (Details Narative) - USD ($)	May 15, 2018	Apr. 26, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 04, 2018
Notes payable				$ 275,000
Debt bear interest percentage				15.00%
Interest expense			305,452	$ 172,800
Proceeds from notes payable				$ 275,000
Debt principal amount					$ 10,000
Common stock issued in connection with May Bridge Notes			228,966
Debt maturity date				Sep. 15, 2017
Common stock issued upon exchange of related party notes payable and interest			150,553
Two Promissory Notes [Member]
Notes payable				$ 275,000
Debt bear interest percentage				10.00%
Interest expense			958	$ 1,188
May Notes [Member]
Interest expense			4,911
Proceeds from notes payable	$ 722,500
Debt principal amount	850,000
Common stock issued in connection with May Bridge Notes	55,000		$ 228,966
Debt net of commissions amount	27,500
Original issue discount	$ 100,000
May Notes [Member] | Minimum [Member]
Debt bear interest percentage			0.00%
May Notes [Member] | Maximum [Member]
Debt bear interest percentage			10.00%
Related Party Note [Member]
Debt bear interest percentage			6.00%
Interest expense			$ 4,078	$ 21,283
Debt maturity date			May 10, 2018
Debt conversion price per share		$ 4.30
Common stock issued upon exchange of related party notes payable and interest		$ 150,553
Debt conversion of convertible debt		35,012

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 02, 2018	Nov. 27, 2018
Income Tax Disclosure [Abstract]
Ownership interest	50.00%		25.00%	25.00%
Net operating loss carryforwards	$ 17,400,000	$ 11,100,000
Net operating loss carryforwards, expiration	Pre-2018 federal and state net operating loss ("NOL") carryovers may be carried forward for twenty years and begin to expire in 2026.
Deduction percentage of taxable income	80.00%
Rresearch and development tax credit carryforwards	$ 200,000
Rresearch and development tax credit carryforwards, expiration	Expire in 2027
Income tax rate, description	On December 22, 2017, which, among things, reduced the United States corporate income tax rate from 35% to 21%.
Income tax rate	21.00%	34.00%
Reduction in deferred tax asset		$ 1,700,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal: Current
Federal: Deferred	(1,710,997)	(138,931)
State and local: Current
State and local: Deferred	(570,332)	(479,833)
Current and Deferred Federal, State and Local, Tax Expense (Benefit)	(2,281,329)	(618,764)
Change in valuation allowance	2,281,329	618,764
Income tax provision (benefit)

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	(21.00%)	(34.00%)
State taxes, net of federal benefit	(7.00%)	(6.00%)
Permanent differences	11.40%	9.40%
True up adjustments	(0.90%)	1.30%
Effect of change in tax rate	0.00%	21.30%
Change in valuation allowance	17.50%	7.90%
Effective income tax rate	(0.00%)	(0.00%)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 5,298,599	$ 3,122,308
Research and development credit carryforwards	185,680	185,680
Intangible assets	152,109	48,629
Property and equipment	30,957	34,974
Accrued salaries		106,400
Stock-based compensation	526,945	419,868
Deferred rent	6,292	1,394
Impairment loss	136,612	136,612
Total gross deferred tax assets	6,337,194	4,055,865
Less: valuation allowance	(6,337,194)	(4,055,865)
Total

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)

Dec. 02, 2018shares

Nov. 27, 2018shares

Oct. 08, 2018USD ($)

Oct. 02, 2018USD ($)

Sep. 25, 2018USD ($)shares

Jul. 16, 2018USD ($)$ / sharesshares

Jun. 04, 2018$ / sharesshares

Mar. 20, 2018USD ($)

Sep. 20, 2017USD ($)

May 01, 2016USD ($)

Apr. 01, 2016USD ($)$ / sharesshares

Jul. 01, 2010USD ($)ft²

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Number of common stock shares issued | shares

2,005

3,334

1,500,000

Rent expenses

$ 348,227

$ 418,358

Future minimum lease payments

1,304,847

Payments to acquire intangible assets

$ 445,200

Sale of stock price per share | $ / shares

$ 5

Number of common stock issed, value

[1]

$ 6,082,444

Initial feasibility cost

$ 200,000

Agreement termination date

Aug. 31, 2019

Development and Manufacturing Agreement [Member]

Payments to acquire intangible assets

$ 445,200

Agreement term

10 years

Sale of stock price per share | $ / shares

$ 8.66

Number of common stock issed, value

$ 4,194,540

Development and Manufacturing Agreement [Member] | Maximum [Member]

Number of common stock shares issued | shares

484,358

New CEO Agreement [Member]

Annual base salary

$ 400,000

New CEO Agreement [Member] | Maximum [Member]

Annual bonus payments percentage

50.00%

Maximum options purchase percentage

6.50%

CFO Employment Agreement [Member]

Annual base salary

$ 250,000

Number of stock option vested | shares

50,000

Number of stock option expected to be vested | shares

100,000

Option exercise price | $ / shares

$ 2.98

CFO Employment Agreement [Member] | Maximum [Member]

Annual bonus payments percentage

30.00%

Number of stock shares granted | shares

150,000

Property Lease Obligation [Member]

Lease term

1 year

7 years

Area of industrial building | ft²

14,507

Security deposit

$ 3,720

$ 26,113

Payment of rent

2,010

$ 21,761

Operating lease, description

Increases by 3% on each anniversary of the lease inception date

Payments increase by 5% every 24 months

Payment for leases

$ 1,860

$ 7,254

Lease expiration

Apr. 30, 2017

Jun. 30, 2017

Renewal lease term

5 years

Rent expenses

$ 26,838

Hancock Jaffe Laboratory Aesthetics, Inc [Member]

Ownership percentage

28.50%

ATSCO, Inc [Member]

Payment on legal cost

$ 809,520

Payment for legal settlements

$ 173,400

Number of common stock shares issued | shares

120,000

ATSCO, Inc [Member] | January 18, 2019 [Member]

Payment on legal cost

$ 810,055

Product liability contingency unasserted claims

500,000

ATSCO, Inc [Member] | January 18, 2019 [Member] | Cross-Complaint

Product liability contingency unasserted claims

$ 173,400

ATSCO, Inc [Member] | Hancock Jaffe Laboratory Aesthetics, Inc [Member]

Ownership percentage

28.00%

Gusrae Kaplan Nusbaum PLLC [Member]

Payment on legal cost

$ 178,926

[1]

net of offering costs of $2,542,555

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 334,203
2020	344,229
2021	354,561
2022	271,854
Total	$ 1,304,847

Temporary Equity (Details Narra

Temporary Equity (Details Narrative) - USD ($)	Jun. 04, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 08, 2017	Mar. 01, 2017
Preferred stock, shares authorized		10,000,000	10,000,000		6,000,000
Preferred stock, shares designated		10,000,000
Series A Preferred Stock [Member]
Preferred stock, shares designated					1,300,000
Convertible note fixed price per share		$ 10
Preferred stock reduced price per share		4.30
Preferred stock dividend in arrears	$ 911,151
Series B Preferred Stock [Member]
Preferred stock, shares designated				2,000,000
Convertible note fixed price per share		12
Preferred stock reduced price per share		$ 4.50
Preferred stock dividend in arrears	$ 107,556
Series A and Series B Preferred Stock [Member]
Preferred stock converted into common stock	1,743,231
Deemed dividend	$ 3,087,591

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)		Dec. 02, 2018	Nov. 27, 2018	Jun. 18, 2018	Jun. 04, 2018	May 01, 2018	Apr. 26, 2018	Oct. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Common stock reverse stock split								1 for 2 reverse stock split
Common stock, shares authorized								60,000,000	50,000,000	50,000,000
Common stock, shares designated									50,000,000
Preferred stock, shares designated									10,000,000
Number of common stock shares issued		2,005	3,334		1,500,000
Value of common stock shares issued	[1]								$ 6,082,444
Stock-based compensation									$ 1,922,455	$ 878,404
Common stock percentage		25.00%	25.00%						50.00%
Consulting Agreement [Member]
Stock options vesting description				Which per the Consulting Agreement with the consultant will vest monthly over next twelve months.
Unvested shares of common stock				6,137
Stock-based compensation				$ 69,176
Chief Medical Officer [Member]
Number of common stock shares issued							44,444
Value of common stock shares issued							$ 200,000
Chief Medical Officer [Member] | Service Agreement [Member]
Monthly fee						$ 15,000
Sole option payable monthly fee description						Its sole option, elect to pay 25% of the monthly fee in company common stock with the number of common stock determined by dividing the 25% of the monthly fee by the closing price of the Company's common stock on the 2nd work day of each month.
Dividing percentage						25.00%
Medical Advisory Board [Member]
Number of common stock shares issued				30,000
Value of common stock shares issued				$ 99,800
Consultants [Member]
Number of common stock shares issued				160,000
Value of common stock shares issued				$ 798,400
Share based compensation granted, shares				20,000
Stock option grant fair value				$ 99,800
Dividing percentage				0.00%
[1]	net of offering costs of $2,542,555

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	Jun. 18, 2018	Dec. 31, 2018	Jun. 04, 2018	May 30, 2018	Dec. 31, 2017
Warrant exercise price per share				$ 6
Series A Preferred Stock [Member]
Convertible note fixed price per share		$ 10
Warrant to purchase shares of common stock			100,570
Warrant exercise price per share			$ 4.30
Placement Agent [Member]
Purchase of common stock warrants		15,339
Convertible note fixed price per share		$ 4.62
Investors [Member]
Convertible note fixed price per share		$ 4.20
Purchasers [Member]
Warrant term			5 years
Warrant to purchase shares of common stock			1,725,000
Warrant exercise price per share			$ 6
Underwriter [Member]
Warrant term			5 years
Warrant to purchase shares of common stock			75,000
Warrant exercise price per share			$ 6.25
Consultants [Member]
Warrant term	5 years
Warrant to purchase shares of common stock	100,000
Warrant exercise price per share	$ 4.99
Grant date value warrant	$ 179,000
Stock price	$ 4.93
Expected volatility	42.60%
Annual rate of quarterly dividends	0.00%
Consultants [Member] | Minimum [Member]
Risk free interest rate	2.67%
Expected term	3 years
Consultants [Member] | Maximum [Member]
Risk free interest rate	2.80%
Expected term	5 years
Common Stock One [Member] | Placement Agent [Member]
Warrant term		5 years			5 years
Purchase of common stock warrants		1,441,298			1,441,298
Common Stock Two [Member] | Placement Agent [Member]
Warrant term		5 years			5 years
Purchase of common stock warrants		138,392			138,392
Common Stock [Member]
Warrant to purchase shares of common stock			116,912
Warrant exercise price per share			$ 4.30

Warrants - Schedule of Stock Wa

Warrants - Schedule of Stock Warrant Activity (Details) - USD ($)		12 Months Ended
		Dec. 31, 2018		Dec. 31, 2017
Common Stock [Member]
Number of Warrants Outstanding Beginning		371,216		416,666
Number of Warrants, Issued		3,292,443		204,550	[1]
Number of Warrants, Exercised
Number of Warrants, Cancelled				(250,000)
Number of Warrants, Amendment of Placement Agent Warrants	[2]	116,912
Number of Warrants Outstanding End		3,780,571		371,216
Number of Warrants, Exercisable		3,780,571
Weighted Average Exercise Price Outstanding Beginning		$ 12		$ 12
Weighted Average Exercise Price, Issued		6.09		12
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Amendment of Placement Agent Warrants	[2]	4.30
Weighted Average Exercise Price, Outstanding End		5.48	[3]	$ 12
Weighted Average Exercise Price, Exercisable		$ 5.48
Weighted Average Remaining Life in Years, Beginning		4 years 1 month 6 days
Weighted Average Remaining Life in Years, Exercisable		4 years 1 month 6 days
Intrinsic Value, Beginning
Intrinsic Value, Exercisable
Series A Preferred Stock [Member]
Number of Warrants Outstanding Beginning		100,570		100,570
Number of Warrants, Issued					[1]
Number of Warrants, Exercised
Number of Warrants, Cancelled
Number of Warrants, Amendment of Placement Agent Warrants	[2]	(100,570)
Number of Warrants Outstanding End				100,570
Number of Warrants, Exercisable
Weighted Average Exercise Price Outstanding Beginning		$ 5		$ 5
Weighted Average Exercise Price, Issued
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Amendment of Placement Agent Warrants	[2]	5
Weighted Average Exercise Price, Outstanding End				$ 5
Weighted Average Exercise Price, Exercisable
Weighted Average Remaining Life in Years, Beginning		0 years		0 years
Weighted Average Remaining Life in Years, Exercisable		0 years		0 years
Intrinsic Value, Beginning
Intrinsic Value, Exercisable
[1]	Warrants granted in 2017 consist of Series B warrants for purchase of 17,303 shares, convertible note debt holder warrants for purchase of 171,908 shares and convertible note placement agent warrants for purchase of 15,339 shares of common stock.
[2]	In connection with the IPO, placement agent warrants for the purchase of Series A Preferred Stock were amended such that the warrants became exercisable for the number of common stock that would have been issued upon the exercise of the Series A warrant and subsequent conversion to common stock upon the consummation of the IPO. The exercise price was amended to the price equal to the total proceeds that would have been required upon the exercise of the original warrant, divided by the amended number of warrant shares. The amendment was accounted for as a modification of a stock award. The Company determined that there was no incremental increase in the fair value for the amendment of the award and accordingly there was no charge to the statement of operations for the years ended December 31, 2018.
[3]	Pursuant to the terms of the warrant, the exercise price of the warrants issued to investors and the placement agent in connection with the sale of the Convertible Notes became fixed at $4.20 per share and $4.62 per share, respectively, at the date of the IPO, based upon the price of stock issued in the IPO.

Warrants - Schedule of Stock _2

Warrants - Schedule of Stock Warrant Activity (Details) (Parenthetical)	Dec. 31, 2018$ / sharesshares
Placement Agent [Member]
Purchase of common stock warrants	15,339
Convertible note fixed price per share | $ / shares	$ 4.62
Investors [Member]
Convertible note fixed price per share | $ / shares	$ 4.20
Note Debt Holder [Member]
Purchase of common stock warrants	171,908
Series B Warrants [Member]
Purchase of common stock warrants	17,303

Warrants - Schedule of Outstand

Warrants - Schedule of Outstanding and Exercisable Warrants (Details) - Warrants [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Warrants Outstanding, Number of Warrants	3,780,571
Warrants Exercisable, Exercisable Number of Warrants	3,780,571
Exercise Price Range 1 [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 12
Warrants Outstanding, Exercisable Into Common stock	Common Stock
Warrants Outstanding, Number of Warrants	183,969
Warrants Exercisable, Weighted Average Remaining Life in Years	4 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	183,969
Exercise Price Range 2 [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 6.25
Warrants Outstanding, Exercisable Into Common stock	Common Stock
Warrants Outstanding, Number of Warrants	75,000
Warrants Exercisable, Weighted Average Remaining Life in Years	4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	75,000
Exercise Price Range 3 [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 6
Warrants Outstanding, Exercisable Into Common stock	Common Stock
Warrants Outstanding, Number of Warrants	1,725,000
Warrants Exercisable, Weighted Average Remaining Life in Years	4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	1,725,000
Exercise Price Range 4 [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.99
Warrants Outstanding, Exercisable Into Common stock	Common Stock
Warrants Outstanding, Number of Warrants	100,000
Warrants Exercisable, Weighted Average Remaining Life in Years	4 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	100,000
Exercise Price Range 5 [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.62
Warrants Outstanding, Exercisable Into Common stock	Common Stock
Warrants Outstanding, Number of Warrants	138,392
Warrants Exercisable, Weighted Average Remaining Life in Years	3 years 10 months 25 days
Warrants Exercisable, Exercisable Number of Warrants	138,392
Exercise Price Range 6 [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.30
Warrants Outstanding, Exercisable Into Common stock	Common Stock
Warrants Outstanding, Number of Warrants	116,912
Warrants Exercisable, Weighted Average Remaining Life in Years	2 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	116,912
Exercise Price Range 7 [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.20
Warrants Outstanding, Exercisable Into Common stock	Common Stock
Warrants Outstanding, Number of Warrants	1,441,298
Warrants Exercisable, Weighted Average Remaining Life in Years	3 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	1,441,298

Stock Based Compensation (Detai

Stock Based Compensation (Details Narrative) - USD ($)

Nov. 27, 2018

Nov. 15, 2018

Oct. 02, 2018

Sep. 24, 2018

Jul. 16, 2018

Jun. 18, 2018

Nov. 21, 2016

Dec. 31, 2018

Dec. 31, 2017

Dec. 02, 2018

Apr. 26, 2018

Dec. 11, 2017

Common stock percentage

25.00%

50.00%

25.00%

Option term

1 year 7 months 6 days

Stock-based compensation

$ 1,922,455

$ 878,404

Stock Options [Member]

Stock options exercise price per share

$ 4.46

Number of stock shares granted

1,520,207

Option exercise price

$ 7.07

$ 10.16

Option term

9 years

Stock-based compensation

$ 864,626

$ 801,624

Unrecognized stock-based compensation expense

$ 758,012

Stock option shares exercisable

1,865,604

CFO Employment Agreement [Member]

Number of non-qualified stock options to purchase shares of common stock

150,000

Stock options exercise price per share

$ 2.98

Stock option granted fair value per share

$ 1.10

Stock option grant fair value

$ 165,000

Stock price

$ 2.98

Risk free interest rate

2.76%

Expected volatility

35.60%

Annual rate of quarterly dividends

0.00%

Expected term

5 years 3 months 19 days

Number of stock option vested

50,000

Number of stock option expected to be vested

100,000

Option exercise price

$ 2.98

Medical Advisory Board Member [Member]

Number of non-qualified stock options to purchase shares of common stock

80,000

Stock options exercise price per share

$ 4.93

Stock options vesting description

The options have a ten-year term and vest monthly over two years

Stock option granted fair value per share

$ 2.21

Stock option grant fair value

$ 176,800

Stock price

$ 4.93

Risk free interest rate

2.85%

Expected volatility

42.60%

Annual rate of quarterly dividends

0.00%

Expected term

6 years

Board of Directors [Member]

Stock option granted fair value per share

$ 0.47

Stock option grant fair value

$ 507,697

Stock price

$ 4.99

Risk free interest rate

2.97%

Expected volatility

35.30%

Annual rate of quarterly dividends

0.00%

Expected term

5 years 2 months 12 days

Number of stock shares granted

1,080,207

Option to purchase shares of common stock percentage

6.50%

Option exercise price

$ 4.99

Option term

2 years

Resigning Directors [Member]

Stock option granted fair value per share

$ 0.50

Stock option grant fair value

$ 15,000

Stock price

$ 1.97

Risk free interest rate

2.89%

Expected volatility

36.10%

Annual rate of quarterly dividends

0.00%

Expected term

5 years 6 months

Number of stock shares granted

10,000

Option exercise price

$ 2.90

Dr. Francis Duhay [Member]

Stock option granted fair value per share

$ 0.56

Stock option grant fair value

$ 100,800

Number of stock shares granted

60,000

Option exercise price

$ 2.57

Option term

3 years

Dr. Francis Duhay [Member] | Restricted Stock Units (RSUs) [Member]

Number of stock option vested

172,472

Number of stock shares granted

29,183

Option exercise price

$ 1.97

Mr. Marcus Robins [Member]

Stock option granted fair value per share

$ 0.56

Stock option grant fair value

$ 100,800

Number of stock shares granted

60,000

Option exercise price

$ 2.57

Option term

3 years

Mr. Marcus Robins [Member] | Restricted Stock Units (RSUs) [Member]

Number of stock option vested

172,472

Number of stock shares granted

29,183

Option exercise price

$ 1.97

Dr. Sanjay Shrivastava [Member]

Stock option granted fair value per share

$ 0.56

Stock option grant fair value

$ 100,800

Number of stock shares granted

60,000

Option exercise price

$ 2.57

Option term

3 years

Dr. Sanjay Shrivastava [Member] | Restricted Stock Units (RSUs) [Member]

Number of stock option vested

172,472

Number of stock shares granted

29,183

Option exercise price

$ 1.97

Nonemployee Director [Member]

Stock price

$ 1.97

Risk free interest rate

2.90%

Expected volatility

36.10%

Annual rate of quarterly dividends

0.00%

Expected term

5 years 3 months 19 days

Maximum [Member] | CFO Employment Agreement [Member]

Number of stock shares granted

150,000

2016 Omnibus Incentive Plan [Member]

Stock option percentage description

The option price must be at least 100% of the fair market value on the date of grant and if issued to a 10% or greater shareholder must be 110% of the fair market value on the date of the grant.

Common stock percentage

3.00%

2016 Omnibus Incentive Plan [Member] | Stock Options [Member]

Stock option shares expired

818,500

14,649

Stock option shares exercisable

131,851

2016 Omnibus Incentive Plan [Member] | Resigning Directors [Member]

Stock price

$ 2.90

Risk free interest rate

2.96%

Expected volatility

36.10%

Annual rate of quarterly dividends

0.00%

Expected term

5 years

Resigning directors period from original issuance date

10 years

2016 Omnibus Incentive Plan [Member] | Robert Anderson [Member]

Stock option grant fair value

$ 12,000

Stock price

$ 0.10

Number of stock shares granted

40,000

Option exercise price

$ 12

2016 Omnibus Incentive Plan [Member] | Robert Doyle [Member]

Stock option grant fair value

$ 12,000

Stock price

$ 0.10

Number of stock shares granted

40,000

Option exercise price

$ 12

2016 Omnibus Incentive Plan [Member] | Steven Girgenti [Member]

Stock option grant fair value

$ 12,000

Stock price

$ 0.10

Number of stock shares granted

40,000

Option exercise price

$ 12

2016 Omnibus Incentive Plan [Member] | Former Director Robert Doyle [Member]

Stock option grant fair value

$ 1,920

Stock price

$ 0.32

Number of stock shares granted

3,000

Option exercise price

$ 7

2016 Omnibus Incentive Plan [Member] | Former Director Robert Anderson [Member]

Stock option grant fair value

$ 1,920

Stock price

$ 0.32

Number of stock shares granted

3,000

Option exercise price

$ 7

2016 Omnibus Incentive Plan [Member] | Former Director Robert Doyle and Robert Anderson [Member]

Stock price

$ 2.90

Risk free interest rate

2.96%

Expected volatility

36.10%

Annual rate of quarterly dividends

0.00%

Expected term

5 years

2016 Omnibus Incentive Plan [Member] | Minimum [Member]

Common stock, capital shares reserved for future issuance

2,500,000

1,650,000

2016 Omnibus Incentive Plan [Member] | Maximum [Member]

Common stock, capital shares reserved for future issuance

4,500,000

2,500,000

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Weighted Average Remaining Life In Years Outstanding	1 year 7 months 6 days
Stock Options [Member]
Number of Options Outstanding beginning | shares	1,422,000
Number of Options, Granted | shares	1,520,207
Number of Options, Forfeited | shares	(146,500)
Number of Options Outstanding Ending | shares	2,795,707
Number of Options Exercisable | shares	1,865,604
Weighted Average Exercise Price Outstanding beginning | $ / shares	$ 10.16
Weighted Average Exercise Price, Granted | $ / shares	4.46
Weighted Average Exercise Price, Forfeited | $ / shares	10
Weighted Average Exercise Price Outstanding Ending | $ / shares	7.07
Weighted Average Exercise Price Exercisable | $ / shares	$ 8.50
Weighted Average Remaining Life In Years Outstanding	9 years
Weighted Average Remaining Life In Years Exercisable	8 years 4 months 24 days
Aggregate Intrinsic Value Outstanding | $
Aggregate Intrinsic Value Exercisable | $

Stock Based Compensation - Sc_2

Stock Based Compensation - Schedule of Outstanding and Exercisable Options (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Options Outstanding, Number of Options	2,795,707
Options Exercisable, Exercisable Number of Options	1,865,604
Exercise Price Range 1 [Member]
Options Outstanding, Exercise Price | $ / shares	$ 12
Options Outstanding, Exercisable Into Common stock	Common Stock
Options Outstanding, Number of Options	120,000
Options Exercisable, Weighted Average Remaining Life in Years	8 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	120,000
Exercise Price Range 2 [Member]
Options Outstanding, Exercise Price | $ / shares	$ 10
Options Outstanding, Exercisable Into Common stock	Common Stock
Options Outstanding, Number of Options	1,149,500
Options Exercisable, Weighted Average Remaining Life in Years	7 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	1,149,500
Exercise Price Range 3 [Member]
Options Outstanding, Exercise Price | $ / shares	$ 7
Options Outstanding, Exercisable Into Common stock	Common Stock
Options Outstanding, Number of Options	6,000
Options Exercisable, Weighted Average Remaining Life in Years	8 years 10 months 25 days
Options Exercisable, Exercisable Number of Options	6,000
Exercise Price Range 4 [Member]
Options Outstanding, Exercise Price | $ / shares	$ 4.99
Options Outstanding, Exercisable Into Common stock	Common Stock
Options Outstanding, Number of Options	1,080,207
Options Exercisable, Weighted Average Remaining Life in Years	9 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	540,104
Exercise Price Range 5 [Member]
Options Outstanding, Exercise Price | $ / shares	$ 4.93
Options Outstanding, Exercisable Into Common stock	Common Stock
Options Outstanding, Number of Options	80,000
Options Exercisable, Weighted Average Remaining Life in Years	9 years 6 months
Options Exercisable, Exercisable Number of Options	20,000
Exercise Price Range 6 [Member]
Options Outstanding, Exercise Price | $ / shares	$ 2.98
Options Outstanding, Exercisable Into Common stock	Common Stock
Options Outstanding, Number of Options	150,000
Options Exercisable, Weighted Average Remaining Life in Years	9 years 6 months
Options Exercisable, Exercisable Number of Options
Exercise Price Range 7 [Member]
Options Outstanding, Exercise Price | $ / shares	$ 2.90
Options Outstanding, Exercisable Into Common stock	Common Stock
Options Outstanding, Number of Options	30,000
Options Exercisable, Weighted Average Remaining Life in Years	9 years 10 months 25 days
Options Exercisable, Exercisable Number of Options	30,000
Exercise Price Range Eight [Member]
Options Outstanding, Exercise Price | $ / shares	$ 2.57
Options Outstanding, Exercisable Into Common stock	Common Stock
Options Outstanding, Number of Options	180,000
Options Exercisable, Weighted Average Remaining Life in Years	9 years 10 months 25 days
Options Exercisable, Exercisable Number of Options

Stock Based Compensation - Sc_3

Stock Based Compensation - Schedule of Outstanding and Exercisable Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Restricted Stock Units Outstanding, Grant Date Closing Stock Price | $ / shares	$ 1.97
Restricted Stock Units Outstanding, Exercisable Into Common stock	Common Stock
Restricted Stock Units Outstanding, Outstanding Number of Units	87,549
Restricted Stock Units Exercisable, Weighted Average Remaining Life in Years	9 years 10 months 25 days
Restricted Stock Units Exercisable, Exercisable Number of Units

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Advances to related party		$ 206,000
Receipts from repayment of related party advances		216,000
Advance outstanding to related party		0
Receipts from collections of note receivable to related party		$ 160,000
Debt instrument interest percentage		15.00%
Debt maturity date		Sep. 15, 2017
Accrued interest expense	305,452	$ 172,800
Related Party [Member]
Accrued interest expense		6,685
Development and Manufacturing Agreement [Member]
Contract revenue cost	$ 70,400	$ 99,600

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

Mar. 12, 2019

Feb. 07, 2019

Jan. 18, 2019

Jan. 07, 2019

Jan. 02, 2019

Dec. 02, 2018

Nov. 27, 2018

Jun. 04, 2018

Jan. 03, 2019

Dec. 31, 2018

May 30, 2018

Dec. 31, 2017

Warrant strike price

$ 6

Number of common stock shares issued

2,005

3,334

1,500,000

Estimated offering fees and expenses

$ 880,679

Subsequent Event [Member]

Payment on legal cost

$ 810,055

Product liability contingency unasserted claims

500,000

Subsequent Event [Member] | Private Placement [Member]

Warrant strike price

$ 1.50

Gross proceeds of private placement offerings

$ 2,714,000

Number of common stock shares issued

2,360,051

Offering price per share

$ 1.15

Number of shares called by warrant entitled to Placement Agent

188,804

Warrant exercise term

5 years

Net proceeds of private placement offerings

$ 2,326,176

Estimated offering fees and expenses

$ 387,824

Subsequent Event [Member] | Cross-Complaint

Product liability contingency unasserted claims

$ 173,400

Subsequent Event [Member] | Dr. Peter Pappas [Member]

Number of stock shares granted

20,000

Stock options vesting description

The options will vest monthly in twenty-four (24) equal installments for each month that he remains a member of the Company’s Medical Advisory Board.

Agreement term

2 years

Subsequent Event [Member] | H. Jorge UlloaMember

Stock option vested

1 year

Issuance of common stock for services

30,000

Stock option granted at exercise price

$ 1.59

Subsequent Event [Member] | Employment Agreement [Member]

Annual base salary

$ 225,000

Stock option vested

3 years

Stock options vesting description

The options vest quarterly, over a 3 year period, with a 1 year cliff.

Subsequent Event [Member] | Employment Agreement [Member] | Ms. Sarner [Member]

Number of stock shares granted

150,000

Stock option exercisable per share

$ 1.59

Subsequent Event [Member] | Alere Agreement [Member]

Monthly fee

$ 7,500

Issuance of warrants

35,000

Warrant strike price

$ 1.59

Subsequent Event [Member] | MZ Agreement [Member]

Agreement term description

The MZ Agreement is for a term of twelve (12) months, that can be cancelled by either party at the end of six (6) months with thirty (30) day notice. After the full twelve (12) month term, the MZ Agreement will automatically renew every (6) months thereafter unless either party to the other delivers written notice of termination at least thirty (30) days notice prior to the end of the then current MZ Agreement.

Received compensation

$ 8,000

Subsequent Event [Member] | MZ Agreement [Member] | Restricted Stock [Member]

Restricted shares that vested

85,000